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Annotation 
Potentially sharing a similar genetic architecture, coronary artery disease (CAD), diabetes 
mellitus and pituitary adenomas (PA) are multifactorial diseases contributing significantly to 
increased mortality and morbidity throughout the world. Decades of studies have discovered 
numerous genetic susceptibility factors for these diseases and high inter-population 
variability. The aim of this doctoral thesis was to investigate the roles and associated 
complications of adenosine A3 receptor (ADORA3) and glyoxalase 1 (GLO1) polymorphisms 
in the susceptibility of CAD and diabetes, respectively, as well as to examine the genetic 
basis of pituitary adenoma (PA) in Latvian population. 
The CAD study included in the thesis found a protective missense polymorphism rs35511654 
in ADORA3, which possibly modulates the damage caused by ischemia, or offers protection 
by reducing inflammation caused by arterial plaques. The second study uncovered the role 
of three GLO1 polymorphisms in the activity of Glo1. Both the rs1130534 and rs1049346 
polymorphisms were associated with a decreased activity or concentration of the Glo1 
enzyme in the blood, but they were not associated with the presence of complications due 
to diabetes. Genetic studies on PA found that the SSTR5 polymorphisms rs34037914 and 
rs642249 are associated with the presence of somatotropinomas, earlier onset of disease, 
and worse clinical outcomes in carriers. The rare MEN1 polymorphism rs2959656 showed a 
strong association with clinically significant PA, regardless of the type of adenoma present. 
Two DRD2 polymorphisms (rs7131056 and rs4938025) are associated with presence of 
extrasellar growth of tumor in hormones secreting PA. This suggests a deeper involvement 
of these variants in PA pathogenesis and possibly shows opportunities for drug therapy 
modulation which currently targets DRD2. The novel findings of these PA studies are 
particularly interesting since the genetic aspects of the common forms of PA are still under-
investigated in European populations. The information from these four published studies 
provides additional insight into the genetic mechanisms contributing towards CAD, diabetes 
complications, and PA in Latvian population and could become a part of improved diagnostic 
systems and targeted medicine. 
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Anotācija 
Koronārā sirds slimība (KSS), cukura diabēts un hipofīzes adenoma (HA) ir multifaktoriālas 
slimības ar līdzīgu ģenētisko arhitektūru un aizvien pieaugošu saslimstību un mirstību visa 
pasaulē. Pētījumi, kas ilguši gadu desmitus, atklājuši lielu skaitu šo slimību ģenētiskos riska 
faktorus un daudz atšķirību starp dažādām populācijām. Šī doktora darba mērķis ir izpētīt 
adenozīna A3 receptora (ADORA3) polimorfismu lomu KSS riska paaugstināšanā, glioksilāzes 
1 (GLO1) polimorfismu ietekmi uz diabētu un tā komplikācijām un HA ģenētiskos cēloņus, 
visos pētījumos fokusējoties uz Latvijas iedzīvotāju populāciju. 
Viens no pētījumiem, kas veikts doktora darba ietvaros ir atklājis pret KSS aizsargājošu 
nesinonīmu polimorfismu rs35511654 ADORA3, kas, iespējams, modulē išēmijas izraisīto 
bojājumu pakāpi vai arī novērš KSS, samazinot iekaisuma reakciju arterialajās pangās. Otrs 
pētījums noskaidroja trīs GLO1 polimorfismu lomu Glo1 aktivitātē, konstatējot, ka rs1130534 
un rs1049346 ir asociēti ar samazinātu enzīma aktivitāti vai tā daudzumu asinīs, bet ne tieši 
ar diabēta komplikāciju klātbūtni. HA pētījumi noskaidroja, ka SSTR5 polimorfismi 
rs34037914 un rs642249 ir asociēti ar augšanas hormonu (GH) sekretējošas HA klātbūtni, 
agrāku slimības iestāšanos un smagāku klīnisko slimības norisi riska variantu nesējiem. 
Plašākā pētījumā arī rets nesinonīms MEN1 polimorfisms rs2959656 uzrādīja būtisku 
asociāciju ar klīniski nozīmīgu HA.  
Tika atklāts, ka divi DRD2 polimorfismi (rs7131056 un rs4938025) ir asociēti ar HA, kam ir 
ekstrasellāra augšana hormonus sekretējošās HA, liecinot par DRD2 plašāku iesaistību HA 
potoģenēzē un parādot iespēju medikamentu terapijas, kura mērķēta uz DRD2  modulācijai. 
Šie četri publicētie pētījumi papildina informāciju par KSS, diabēta komplikāciju un HA 
ģenētiskajiem mehānismiem Latvijas populācijā un šī informācija var dot pienesumu 
uzlabotā diagnosticēšanā un personalizētās medicīnas attīstībā. 
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Abbreviations 
A1R, A2AR, A2BR, A3R, AR – adenosine A1, A2A, A2B, A3 receptor, adenosine receptor 
ACTH – adrenocorticotropic hormone 
ADHs – aldehyde dehydrogenases 
AGEs – advanced glycation end products 
AKRs – aldoketo reductases  
AP-2α – activating enhancer-binding protein 2α 
ATP – adenosine triphosphate 
AUC – area under curve 
BMI – body mass index 
CAD – coronary artery disease 
Chr – chromosome 
CNC – Carney complex 
CREB – cAMP response element-binding protein 
CST – cortystatin 
CVD – cardiovascular disease 
DNA – deoxyribonucleic acid 
dNTP – deoxynucleotide 
ddNTP – dideoxynucleotide 
E2F4 – early gene 2 factor isoform 4 
EGF – epithelial growth factor 
FHS – Framingham Heart Study 
FIPA – familial isolated pituitary adenoma 
GH – growth hormone 
GSH – glutathione 
GWAS – genome wide association studies 
ICD-10 – International Classiﬁcation of Diseases 
IGF-I – insulin-like growth factor 1 
Indiv – individuals 
INFγ – interferon gamma 
IRE – insulin-response element 
kb – kilobases 
LDL – low-density lipoprotein 
LGDB – Latvian Genome Database 
MAF –minor allele frequency 
MALDI-TOF –matrix-assisted laser desorption/ionization time of flight 
MEN – multiple endocrine neoplasia 
MG – methylglyoxal 
MI – myocardial infarction 
mmol/L – millimoles per liter 
mPTP – mitochondrial permeability transition pore 
MRE – metal-response element 
MRI – magnetic resonance imaging 
mRNA – messenger ribonucleic acid 
N – number 
NFPA – non-functional pituitary adenoma 
Nrf2 – erythroid 2-related factor 2 
OR – odds ratio 
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PA – pituitary adenoma 
PCR – polymerase chain reaction 
PIT1 – pituitary-specific positive transcription factor 1 
PKA – protein kinase A 
PRL – prolactin 
rs#### – reference SNP #### 
SAP – shrimp alkaline phosphatase 
SNP – single nucleotide polymorphism 
SST – somatostatin 
T2D, T1D – type 2 diabetes, type 1 diabetes 
TSH – thyroid-stimulating hormone 
X-LAG – Xq26.3 duplication acrogigantism 
Genes and proteins 
AIP - aryl hydrocarbon receptor interacting protein  
AKT - Protein kinase B  
ALOX5AP - Arachidonate 5-Lipoxygenase Activating Protein 
ANGPTL4 - Angiopoietin Like 4  
ANRIL - CDKN2B Antisense RNA 1  
APOE, APOA5, APOC3 - Apolipoprotein E, Apolipoprotein A-V, Apolipoprotein C-III  
ARHGEF6 - Rac/Cdc42 Guanine Nucleotide Exchange Factor 6  
CD40LG - CD40 Ligand 
CDH23- cadherin-related 23  
CDKN2B, CDKN2A - Cyclin Dependent Kinase Inhibitor 2B, 2A  
CREB - cAMP response element-binding protein  
DRD2 – Dopamine Receptor D2  
EBF1 - Early B-Cell Factor 1  
ExoI – Exonuclease I E. coli  
G i/o – G protein with inhibitory alpha subunit  
GLO1 -  Glyoxalase I 
GNAS - (guanine nucleotide binding protein, alpha stimulating) complex locus  
GPR101 - G Protein-Coupled Receptor 101  
GRB10 - Growth Factor Receptor Bound Protein 10  
Gs/olf – G protein with activating of adenylate cyclase alpha subunit/in olfactory receptors 
GTP-ase - guanosine triphosphate hydrolyze   
HAGH - Hydroxyacylglutathione Hydrolase  
HMG-CoA - 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase, HMGCR  
IARS - Isoleucyl-TRNA Synthetase  
KIF5A - Kinesin Family Member 5A  
LDLR - Low Density Lipoprotein Receptor  
LOC400684 - Uncharacterized LOC400684  
LPL - Lipoprotein lipase  
LTA - Lymphotoxin Alpha  
LTA4H - Leukotriene A4 Hydrolase  
MEF2 - Myocyte Enhancer Factor 2  
MEN1 - Menin 1  
MGMT - O-6-Methylguanine-DNA Methyltransferase  
MKI67 – Antigen KI-67  
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MTAP - Methylthioadenosine Phosphorylase  
mTOR – FK506-binding protein 12-rapamycin-associated protein 1  
NR3C1 - Nuclear Receptor Subfamily 3 Group C Member 1  
PCSK9 - Proprotein Convertase Subtilisin/Kexin Type 9  
PI3K Phosphatidylinositol-4,5-bisphosphate 3-kinase  
PI3KCA - Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha  
PIT1 - Pituitary-specific positive transcription factor 1  
PKA – Protein Kinase A  
PRKAR1A - Protein Kinase CAMP-Dependent Type I Regulatory Subunit Alpha  
RBMX - RNA Binding Motif Protein, X-Linked  
SP100 - SP100 Nuclear Antigen  
SST5TDM5, SST5TDM4 – Somatostatin Receptor 55 consisting of five or four transmembrane 
domains  
SSTR1, SSTR2, SSTR3, SSTR4 and SSTR5 - Somatostatin Receptor 1; 2; 3; 4 and 5  
THBS1, THBS2, THBS4 - Thrombospondin 1, 2, 4  
TNFRSF13C - TNF Receptor Superfamily Member 13C  
TRIP12 - Thyroid Hormone Receptor Interactor 12  
USP8 - Ubiquitin Specific Peptidase 8  
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Introduction 
Coronary artery disease (CAD), diabetes mellitus and pituitary adenoma (PA) are 
multifactorial diseases of similar genetic architecture that are contributing to increased 
mortality and morbidity rates throughout the world. They are caused by an interaction 
between numerous environmental and genetic risk factors. Most of the associated 
environmental risk factors were discovered and intensely studied in the second half of the 
20th century. With the advancement of technology, multiple studies have searched for 
genetic susceptibility factors for these diseases. This has led to tens to hundreds of genes 
being identified and implicated in CAD, diabetes and PA. Their intermediate risk factors, 
complications and phenotypic modifications have also been described. Lately, this genetic 
research has started to impact decision-making in clinical settings since more and more 
evidence points towards the value of genetic information in improving prognoses, 
performing risk assessments and even informing treatment strategies or drug doses. 
However, not all genetic risk factors are known, while even less is known about their 
interaction with other genetic and environmental risk factors. Since huge inter-population 
variation exists, a large area for research studies is provided. It is also clear that less 
attention has been paid to the investigation of the genetics of numerous clinical phenotypes 
and the outcomes associated with each of the large multifactorial disease groups. Similarly, 
despite the advancements in GWAS technology, the number of genetic studies conducted on 
rare multifactorial diseases like PA is limited. In order to increase the general knowledge of 
genetic risk factors underlying these conditions and by paying special attention to the 
specific clinical characteristics and sub-phenotypes, the aim of the research was to study the 
genetic causes and aspects of multifactorial diseases (CAD, diabetes complications and PA) in 
Latvian population. To achieve the proposed aim of the study, the following tasks were 
established: 
1. To investigate the role of ADORA3 variations in CAD susceptibility in Latvian population; 
2. To study GLO1 polymorphisms and assess the associated functional Glo1 activity in 
connection with common type 1 and type 2 diabetes complications; 
3. To identify SSTR5 mutations in pituitary adenoma patients and to study their impact on 
the clinical characteristics of somatotropinomas; 
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4. To scan the tag-SNPs of seven candidate genes (SSTR5, SSTR2, DRD2, GNAS, MEN1, AIP, 
PRKAR1A) in search of common mutations causing pituitary adenomas and to understand 
how they influence phenotypic characteristics in Latvian population. 
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1. Literature review 
1.1 Multifactorial diseases 
Most human diseases and disorders result from a complex interplay between multiple 
genetic and environmental factors (Lander and Schork 1994). These conditions are 
commonly called multifactorial diseases or disorders. Multifactorial diseases occur when 
combination of genetic and environmental factors (often not completely known) interact, 
but these interactions are not yet identified or not known in details. Due to these unknown 
facts multifactorial diseases are difficult to study, prevent and treat. Uncovering genetic 
factors underlying mechanisms of multifactorial diseases can lead to better diagnosis, risk 
prediction, management of healthcare funds, discovery of new drug targets, and 
understanding of disease prevention as well as improved general and precision treatment of 
the disease (Vieira 2014). 
In multifactorial diseases there is no clear gradation of phenotype. Number of characteristics 
of multifactorial diseases distinguishes them from Mendelian or sex-dependent disorders 
(Lobo 2008). The multifactorial disease can be sporadic, with affected offspring born to 
unaffected parents and when there is aggregation of disease cases in the family, no 
Mendelian pattern of inheritance can be observed (Mossey 2002). The risk of the disease is 
modified by environmental factors such as pollution, lifestyle, viral infections and others 
(Ralston 2008). The disease is more frequent in one sex than in other but is not sex 
dependent (Lobo 2008). The percentage of twin pairs in which both twins are affected by 
disease does not follow Mendelian proportions in both monozygotic and dizygotic twins 
(Mossey 2002). And the disease is more frequent in a specific population (Clark and Emerole 
1995). 
A classic example of this is coronary artery disease (CAD) with many factors increasing the 
risk like diabetes, elevated blood pressure and increased LDL cholesterol concentration. CAD 
does not show Mendelian inheritance although having family member with CAD is one of 
risk factors. Up to 90% of CAD risk is preventable by modifying environment (food, exercise 
and pollution) and it is more common in men than women as well as in Africans than Asians 
or Europeans. All of these characteristics are consistent with the definition of multifactorial 
disease (Castelli et al. 1986, Doyle et al. 1962, Yusuf et al. 2004, Kannel et al. 1961, Kannel et 
al. 1971, Kannel and McGee 1979, Keys et al. 1963, Keys 1980). 
Several problems of studying multifactorial diseases are highlighted in table 1. 
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Table 1. Challenges in multifactorial disease research (Kullo and Ding 2007) 
Issue Description 
Heterogenity 
of phenotype  
Multifactorial diseases clinical manifestations are diverse, for example CAD 
can present itself as stable angina, myocardial infarction, acute coronary 
syndrome and sudden cardiac death. Also classification can be dichotomous 
(presence or absence) or continuous (measurements of coronary artery 
calcification).  
Heterogenity 
of genotype 
Genetic heterogeneity is very likely due to different pathways that can lead 
to multifactorial disease. In case of pituitary adenomas (PA) several 
monogenic forms are known, somatic mutations in GNAS are common in 
somatotropic PA and several genetic variants are associated with 
development and characteristics of human PA. Even more genetic 
heterogeneity is pronounced in CAD, where several CAD risk factors (low-
density lipoprotein (LDL) cholesterol, triglycerides) are themselves 
influenced by genetic variants. 
Low 
influence of 
individual 
gene 
Single genetic variant usually contributes only tiny proportion towards 
multifactorial disease phenotype. Low odds ratio (OR) 1.1-1.5 is common 
contribution of individual genetic variant. To discover such influence large 
cohorts of cases and controls are necessary which in turn have provided 
incentive to establish and develop population based genome biobanks in 
many countries. 
Gene-gene 
and gene-
environment 
interaction 
To establish contribution of gene-gene and gene-environment interactions 
towards risk and pathophysiology of multifactorial disease with sufficient 
even larger sample sizes are necessary or new methods of quantifying 
interaction must be developed. Nevertheless it could be important part of 
“mission heritability” in multifactorial diseases. 
Rare causal 
variants of 
multifactorial 
diseases 
Majority of genome wide association studies (GWAS) assumed that 
multifactorial diseases are caused by common genetic variations. Most 
likely both common and rare variants are involved in development of 
multifactorial diseases. To discover rare variants ever larger sample size is 
needed and combination with functional research is necessary. 
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Another aspect of genetic research of multifactorial diseases is possible use of genetic 
markers to improve risk prediction and reclassification of patients. Currently multiple studies 
have focused on use of GWAS data in cardiovascular disorders and diabetes, including 
complications (meta-analysis (Muller et al. 2016)). 
The main recommendations as of 2017 of using genetic markers in risk prediction and 
studies of risk prediction in multifactorial diseases are:  
 Evaluation of the baseline model predicting the risk of disease. As baseline model 
becomes better the harder it is to improve it. This evaluation helps to understand 
how much improvement of risk assessment can be expected from addition of genetic 
information(Muller et al. 2016). 
 Bias avoidance is necessary. Identification of potential sources of bias and negation 
of its effects must be included in risk prediction study design. The best strategy 
would be to select and evaluate model in separate, independent training and testing 
cohorts. Also resampling methods could be used as less powerful substitute 
(Steyerberg et al. 2001). 
 Genetic variants included in the risk assessment must be well validated, preferably in 
several studies across different populations. Information about the effects should be 
updated regularly as new studies are published modifying current knowledge. 
 More studies are necessary to unravel molecular basis of intermediate phenotypes of 
the multifactorial disease and how these variations relate to the disease in question. 
 Models of risk prediction are more likely to be more powerful when weighted risk of 
the alleles is used than simple counts of risk alleles. 
 Evaluation and reporting of more than one quality measure that complement each 
other should be encouraged. Area under curve (AUC), reclassification measures, 
recalibration and measures of clinical relevance (number needed to screen) helps to 
compare various studies, interpret relevance and make decision about potential use 
of genetic markers (Muller et al. 2016). 
Meanwhile research of PA also have identified multiple causes of PA and multiple modifiers, 
that can lead to enhancement of precision treatment strategies of PA not only by stratifying 
into currently used broad PA type groups but also peering into subdivisions of the disorder 
(Syro et al. 2015). 
Research into multifactorial diseases is expected to spark new and advanced possibilities in 
precision medicine - prevention and treatment of disease that is tailored to individual 
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variability. This concept is not new, because blood typing to guide blood transfusion is in use 
for more than century and use of CYP2C19 genotyping is recommended in prescription of 
anticoagulant clopidogrel ((FDA) 2010). But there is also emerging evidence of precision 
medicine in its broader scope to provide great results in multifactorial diseases such as 
cancer (de Bono and Ashworth 2010). 
Several hurdles exist for precision medicine, but by discovering how can patient benefit and 
how much does it cost to healthcare will help to overstep these limitations (Collins and 
Varmus 2015). 
Summary of four peer reviewed publications of genetic research of multifactorial diseases in 
Latvian population are presented in this work. 
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1.2 Overview of CAD and its genetics 
1.2.1. Anatomy and physiology of cardiovascular system 
The cardiovascular system is part of a circulatory system in the humans and other animals 
with closed (blood never leaves network of blood vessels) cardiovascular system. It consists 
of heart, three main types of blood vessels (arteries, veins and capillaries) and blood itself. 
Cardiovascular system has range of functions with most obvious being transport of nutrients 
(carbohydrates, amino acids, fatty acids, ions and vitamins), oxygen, carbon dioxide, heat, 
hormones and other signaling molecules as well as cells throughout the body. It is an integral 
part of immunity necessary for fighting infections. Transport functions also helps to regulate 
and maintain optimal conditions for cells of the body by stabilizing temperature and pH level 
(Graaff 2001). 
Heart is the central unit of the cardiovascular system by moving blood throughout the body. 
Arteries and arterioles are muscular and elastic blood vessels that carry blood leaving heart. 
Their anatomy reflects need to resist pulsating pressure of the blood and deliver it to the 
organs and tissues of the body Figure 1. It is the arteries that are damaged in case of CAD 
and their dysfunction leads to pathophysiology of CAD. 
Figure 1. Anatomy of the arterial wall (Blausen 2014). 
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Capillaries create microvasculature and ensure that every cell of the organism receives 
nutrients and oxygen, stays connected to the rest of the body and removes waste products 
of cellular metabolism. 
Although heart is filled with blood, oxygen and nutrients cannot be used by heart muscle 
(myocardium) directly. Coronary circulation delivers these essentials to the myocardium and 
other components of the heart via coronary arteries. This is an “end circulation” system 
meaning that there is almost no redundancy and reason why blockage of one vessel is so 
critically dangerous for whole organism. 
Coronary arteries begin at left side of the heart at the base (root) of the aorta. Three aortic 
sinuses are located in the aortic wall superior to the aortic semilunar valve. Two of these 
sinuses are beginning of the left and right coronary arteries. Branches of coronary arteries 
that remain on the surface of the heart are called epicardial coronary arteries, but branches 
that are inside myocardium are referred as subendocardial coronary arteries. Coronary 
arteries are self-regulating to maintain optimal blood flow required by the myocardium. If 
there is lack of oxygen in the myocardium due to decrease of blood flow tissue ischemia 
occurs. Short term ischemia causes intense chest pain (angina). Prolonged and severe 
ischemia may result in death of heart or part of myocardium (event known as myocardial 
infarction) (Graaff 2001). Sudden restoration of blood flow is also dangerous to the cells of 
myocardium due to creation of reactive oxygen radicals from the anaerobic metabolites 
(process described as ischemia-reperfusion injury) (Yellon and Hausenloy 2007).  
Chronic moderate ischemia leads to myocardial hibernation – condition with weakened 
heart contractions.  
Coronary circulation has unique characteristics in response to different stresses, drugs and 
hormones. For example, in adrenergic stimulation most blood vessels constrict in response 
to norepinephrine and blood pressure is increased, but due to relatively higher amount of 
beta-adrenergic receptors in coronary circulation, coronary arteries dilate and increase 
blood flow in order to supply heart with nutrients and oxygen in higher workload 
environment (Graaff 2001). 
1.2.2. Coronary artery disease 
Coronary artery disease (CAD) (also known as coronary heart disease, acute coronary 
syndrome, ischemic heart disease) is the most common of cardiovascular diseases (CVD). 
CAD is usually defined with well-established clinical manifestations such as stable and 
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unstable angina, nonfatal myocardial infarction (MI), and coronary death. Also CAD can be 
defined by healthcare procedures such as Coronary artery bypass grafting and percutaneous 
coronary intervention (including stenting and angioplasty) performed to the patient (Wong 
2014).  
1.2.3. Mechanisms of CAD 
The basis of CAD pathology is atherosclerosis in coronary heart arteries which is 
characterized with endothelial dysfunction and narrowing of arterial lumen increasing over 
time. Atherosclerosis itself is mainly driven by inflammation processes at the sites of 
damaged endothelium (Libby 2002). In this process fatty atheromatous plaques are 
developing under the endothelium in the arterial tunica intima (located between 
endothelium and tunica media in the wall of artery) Figure 2. 
Figure 2. Phases and progression of the atherosclerosis (Anonymous 2006). 
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Plaque formation is slow, usually continuing over several decades. Interaction between risk 
factors, cellular events and response to these in arterial wall is the cause of plaques (Libby 
and Theroux 2005). “Response to the injury” is the main theory currently accepted among 
scientists and medical scholars about development of atherosclerosis. Plaque formation is 
triggered by physical and chemical injuries to the endothelial cell layer of arteries (Libby 
2002). Main factors causing this injury are physical damage (as a result of direct trauma or 
hypertension), turbulent blood flow (branching areas of the arteries), circulating reactive 
oxygen species and pollutant particles (from smoking or air pollution), hyperlipidemia (high 
blood concentrations of LDL and very low-density lipoprotein), chronically elevated blood 
glucose and other (Castelli et al. 1986, Doyle et al. 1962, Kannel et al. 1961, Kannel et al. 
1971, Kannel and McGee 1979, Keys et al. 1963, Keys 1980). These factors also predispose 
plaque formation in certain areas of the arteries (Samady et al. 2011). 
Endothelial cells in the blood vessel provide semi-permeable barrier between the liquid 
blood and wall of the blood vessel which is actively involved in several critical roles for the 
organism. The main function is to regulate exchange of nutrients, gases, water and waste 
between the blood and tissues. Endothelial cells also regulate diameter of the blood vessels 
by synthesizing and releasing nitric oxide and prostacyclin (PGI2) to relax blood vessels and 
endothelin and angiotensin-II to constrict them. These molecules also help to maintain blood 
pressure (Lerman and Zeiher 2005). 
Endothelium also provides surface that allows blood to flow without sticking to blood vessel 
walls. When there is an injury to the endothelium inflammatory response is triggered by 
secretion of cytokines. Also endothelium cells start producing molecules that ensure surface 
adhesion which causes monocytes and T-lymphocytes to migrate under the endothelium. 
Endothelial cells near the injured site also change shape and loosen gaps between cells so 
that monocytes and T-lymphocytes can cross the endothelium. This causes lipoprotein and 
especially low-density lipoprotein (LDL) particles to enter arterial wall and oxidize due to 
presence of vasodilator molecule NO, macrophages and lipoxygenase. Additional circulating 
monocytes are invading injury because of released chemokines (such as IL-8 (Novo et al. 
2015)), they differentiate into macrophages and start to uptake oxidized LDL. This in turn 
changes their morphology and in time they are so full of lipids that change appearance to 
“foam” cells. “Foam” cell phase will trigger apoptosis and it will die, but lipids and debris 
from all the apoptotic cells will cause inflammation to increase beginning self-driven process 
of plaque growth in the wall of the artery (Libby 2002). 
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Meanwhile T lymphocytes secrete cytokines inviting smooth muscle cells to cross internal 
elastic membrane of the artery wall. These smooth muscle cells start to proliferate due to 
influence of growth factors. Together with accumulation of lipids, cell debris and calcium 
deposits smooth muscle cells contribute towards growth of plaques and remodeling of 
arterial walls. Two types of plaques are found in the wall of arteries: “stable” plaques with 
relatively small lipid pool and thick fibrous cap, usually preserving lumen of artery, and 
“vulnerable” plaques characterized with large pool of lipids, partially obstructed lumen, thin 
fibrous cap and large number of inflammatory cells. Former usually lead to stable 
atherosclerosis and few clinical CAD signs. Latter type of plaques are more prone to rupture 
and thrombosis which is especially dangerous in coronary arteries of the heart (Libby 2002). 
Stenosis or blockade of blood vessel is event of advanced atherosclerosis, but may never 
occur to the individual. Complete blockage or 100% stenosis is common cause of the most 
dangerous CAD endpoints, especially miocardial infarction (Davies 1996). 
1.2.4. Risk factors of CAD 
The main risk factors of CAD are described as modifiable such as type 2 diabetes, 
hyperlipidemia, smoking, hypertension and increased C-reactive protein level in the blood. 
Non-modifiable CAD risk factors are age (above 45 for men and above 55 for women), 
genetic predisposition and male sex. Low impact risk factors are adiposity, sedentary 
lifestyle, elevated triglyceride levlel and increased serum homocysteine (Berenson et al. 
2016, Castelli et al. 1986, Doyle et al. 1962, Kannel et al. 1961, Kannel et al. 1971, Kannel and 
McGee 1979, Keys et al. 1963, Keys 1980, Wilcken and Wilcken 1976). 
1.2.5. Diagnosis 
Two to three decades ago the main focus for diagnosis of advanced CAD was detection of 
narrowing of arterial lumen using angiography and sometimes physical “stress testing”. But 
human clinical studies have shown that plaque rich sites with no to low lumen narrowing are 
the most prone to rupture and cause the occlusion of artery (and life threatening CAD 
endpoint) within minutes. This is supported by the findings that only about 14% of clinically 
relevant CAD events are at sites with lumen stenosis over 75%(Maseri and Fuster 2003). 
Majority are caused by sudden plaque rupture. Therefore currently main emphasis is 
detection of aterial wall remodelling. Anatomical methods are more precise and allow to 
monitor disease progression, but require more resources and sometimes are invasive. 
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Coronary calcium scoring by computer tomography, carotid intimal media thickness 
measurement by ultrasound, and intravascular ultrasound are anatomical methods that 
attempt to detect and quantify vulnerable plaques and with subsequent visits monitor CAD 
progression. Circulating biomarker measurement methods use lipoprotein subclass analysis, 
glycated hemoglobin or HbA1c, high-sensitivity C-reactive protein, and homocysteine to 
detect CAD before clinically relevant symptoms are visible. Recent additions of diagnostic 
techniques are positron-emission tomography and single-photon emission computed 
tomography imaging to investigate and quantify plaques (Beller and Heede 2011). 
1.2.6. Epidemiology 
CAD is the most prevalent of CVD and is cause 46% of cardiovascular deaths for men and 
38% for women (Wong 2014). And for up to third of the cases the cardiovascular death is the 
first manifestation of CAD. It is a multifactorial disease which is caused by combination of 
genetic, environmental and lifestyle factors. 
Studies have shown that CAD causative atherosclerosis initiates before age of 20, but usually 
clinical manifestations appear after several decades. Atherosclerosis increases more rapidly 
after age of 30 in some cases but more typical age of notable plaques is beyond 50 or 60 
years. 
The incidence of CAD and the prevalence of important risk factors vary greatly according to 
geographical region, sex, and ethnic background (Wong 2014). 
1.2.7. Historical CAD studies 
Already in 1880s there was notion that there is lack of data about heart disease (Hirsch 
1883). The first prospective study of heart disease was started in 1946 in Minnesota, USA 
involving men as the study subjects (Keys et al. 1963). Experience and knowledge obtained 
from the Minnesota studies of CVD in men led to development of The Seven Countries Study 
and the era of modern CVD epidemiology (Keys 1980). It was proposed that serum 
cholesterol is cause of CAD and that there is difference in CAD frequency between countries 
in 1953 (Keys et al. after (Wong 2014)). The Seven Countries Study established basis of the 
current understanding in CVD (including CAD) risk factors deriving from diet and lifestyle by 
analyzing data of 12763 men aged 40-69 across multiple geographic regions. The main 
discovery of the study was that blood cholesterol was directly associated with CVD across all 
populations involved in the study (Keys 1980). 
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By this time Framingham Heart Study (FHS) had given its first report that CVD is age and sex 
related as well that elevated blood pressure, cholesterol levels and obesity are strong 
predictors of CVD (Dawber et al. 1957). Further role of CVD risk factors was elaborated in 
series of representative publications describing role of cholesterol (Kannel et al. 1971), 
smoking (Doyle et al. 1962) and high blood pressure (van den Hoogen et al. 2000). FHS also 
identified negative correlation between high-density lipoprotein and CVD independent of 
total cholesterol level in the blood (Castelli et al. 1986) as well as important link between 
CVD and diabetes (Kannel and McGee 1979). It demonstrated that several risk factors can be 
combined further elevating the risk and was the first that developed and introduced CVD risk 
assessment for the individual (Framingham Risk Score) still in use in clinical cardiology, 
where it is used as reference in many modern cardiovascular research proposals and 
comparisons (Wilson et al. 1998) 
1.2.8. Genetic architecture of CAD 
CAD is multifactorial disease therefore risk for each individual is composed of genetic, 
environmental and lifestyle factors as well as their combination and interaction (Khera et al. 
2016) CAD heritability was supported by clinical observations in the middle of 20th century 
(Gertler et al. 1951) and further confirmed by study of 20000 Swedish twins which estimated 
heritability for fatal CAD of ~50% (Marenberg et al. 1994, Zdravkovic et al. 2002). Using 
current genome wide data and updated methods CAD heritability was estimated 40-50% 
(Won et al. 2015) which is similar to the Swedish twin study. FHS also found that family 
history of cardiovascular disease in a parent or sibling was severely increasing risk of CAD 
incidence (Lloyd-Jones et al. 2004, Murabito et al. 2005). 
These were the pioneering studies that started research in genetics of CAD, understanding 
molecular mechanisms of the disease and how to translate them into clinical practice (Khera 
and Kathiresan 2017). 
Historically three types of research methods mostly have been used to unravel details about 
genetic details underlying CAD in humans. Family linkage studies, where relatives with and 
without CAD across several generations had their genome mapped and causative locus 
(preferably) identified. Candidate gene studies did research of one to several genes or 
genetic variations (based on hypothesis about plausible involvement of gene or variant in 
CAD) using groups of unrelated individuals (cases and controls). Latest research focuses on 
whole genome approach investigating either hundreds of thousands of genetic variants 
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across genome or sequencing whole or large parts (usually exome) of the genome. Latter is 
hypothesis free approach with aim to find all genetic risk factors and estimate their 
contribution towards development of CAD (Franchini et al. 2008) 
Information from genotyping is used to investigate association between phenotype and 
genotype. Association basis is difference of observed allele frequency between case and 
control groups. Results usually are reported as odds ratio (OR) with confidence interval 
(industry standard is 95%). Control group is reference, therefore OR above one describes 
genetic variant with increased relative risk, but less than one – decreased relative risk 
(Franchini et al. 2008). 
CAD end and intermediate phenotype is multifactorial and many genetic variants can lead to 
similar clinical endpoints. Wide range of genetic variants is responsible for increased risk and 
susceptibility of CAD. Some are located in genes of receptors, structural proteins and 
enzymes of metabolic pathways (regulating blood pressure, lipid metabolism, coagulation, 
growth and inflammation), while most of the latest studies have found strongest 
associations in intergenic regions (Nikpay et al. 2015). 
1.2.9. Candidate gene studies 
Hundreds if not thousands of candidate gene studies have been performed in search of 
genetic risk factors of CAD across many populations and racial backgrounds. 
Initially candidate gene studies were using relatively low number of cases and controls and 
those were predominantly of European descent. Results were rarely replicated and many 
studies attempting to replicate previous findings were prone to lack of power themselves 
(Morgan et al. 2007). 
The first attempt to replicate large amount of previous discoveries of associations of 
candidate genes with CAD were published in 2007. It was focusing on studies published 
before March 10, 2005. This study tested 85 variants in 70 genes in 811 cases and 650 age- 
and sex-matched controls. Study group was European descent. Results revealed that only 
one out of 85 genetic variants show significant association before correction for multiple 
testing. Moreover just 41 (48.2%) of designated risk alleles were more frequent in cases than 
in controls while one was completely identical (Morgan et al. 2007). 
But some controversy remains as this study failed to validate variants that were replicated in 
other studies. APOE4 allele was replicated as increasing risk of CAD (Song et al. 2004). Also 
THBS1, THBS2 and THBS4 were associated with CAD in publication of Topol et al. (Topol et al. 
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2001) and THBS1 replicated by (Zwicker et al. 2006) as risk factor with early (before age 45) 
myocardial infarction. While other studies especially GWAS have failed to demonstrate 
association (Morgan et al. 2007, Nikpay et al. 2015) or showed trend of association with 
early CAD in case of THBS2 and THBS4 (McCarthy et al. 2004). 
Recently there have been upsurge of large, well designed candidate gene studies in CAD in 
populations (East Asian in particular) that are not European descent which were dominating 
CAD candidate gene studies in late 20th and first decade of 21st centuries (Jin et al. 2014, 
Zhang et al. 2013, Zhang et al. 2017). 
1.2.10. Family lnkage studies 
Family linkage studies are very successful in discovery of basis of monogenic diseases and it 
was hypothesized that they will be as insightful for CAD. Family linkage studies use 
knowledge of Mendel’s laws of inheritance that propose equal distribution of genetic 
markers within family. It investigates whole genome for markers that are associated with 
presence of disease. Then fine mapping is performed with expectation to find causal gene. 
Main family linkage study results in CAD studies are shown in table 2. Yet like candidate gen 
studies replication of results proved difficult despite high quality design of the studies. Also 
fine mapping of the locus often were not enough to narrow down causal genetic variation or 
even gene (Franchini et al. 2008). 
Table 2. Main familial linkage studies of CAD (based on (Franchini et al. 2008)).  
Study 
author Year 
Population 
screened Study sample 
Clinical 
event Chr locus 
LOD 
score 
Gene 
identified 
Pajukanta 2000 Finland 156 families (344 indiv) Early CAD 
2q21-22 
Xq23-26 
3,7 
3,5 - 
Francke 2001 Mauritius 99 families (525 indiv) CAD 16p13 3,06 - 
Broeckel 2002 Germany 513 families (1406 indiv) Early CAD 14 3.9 - 
Harrap 2002 Australia 61 families (161 indiv) CAD 2q36 2,6 - 
Wang 2003 USA 1 family (25 indiv) CAD or MI 15q26 4,19 MEF2 
Helgadottir 2004 Iceland 296 families (2454 indiv) MI 13q12-13 2,86 ALOX5AP 
Hauser 2004 USA 238 families (1168 indiv) Early CAD 3q13 3,3 - 
Samani 2005 United Kingdom 1933 families (4175 indiv) CAD /MI 2q14-21 1,15 - 
Helgadottir 2006 Iceland 296 families (2454 indiv) MI 12q22 NZ LTA4H 
Farral 2006 Europe 2036 families (2658 indiv) CAD /MI 17q21 2,68 - 
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1.2.11. GWAS 
Research of CAD genetics using GWAS approach started in the early 21st century and the first 
results were published in 2002 by Ozaki et al. showing association of five LTA single 
nucleotide polymorphisms (SNPs) with MI in Japanese population. Genotyping “only” 93000 
SNP it was a frontrunner of a modern GWAS era. Functional research of missense SNP 
(Thr26Asn) in LTA revealed doubling of synthesis of adhesion molecules in smooth muscle 
cells of the blood vessels including coronary heart arteries. Another SNP in the first intron of 
the LTA increased its transcription (Ozaki et al. 2002). Yet this and some other early GWAs 
discoveries were not replicated later in larger and more powerful studies (Table 3). 
As of 2017 about 100 loci across human genome have been associated with CAD (MacArthur 
et al. 2017) (Table 3).  
Table 3. Main GWAS studies of CAD (MacArthur et al. 2017). 
Author Year Population Sample cases/controls 
Validation 
sample 
New 
CAD 
loci 
Replicated 
previously 
Samani 2008 European 1926/2938 875/1644 7 0* 
WTCCC 2008 European 1926/2938 875/1644 5 0* 
Helgadottir 2008 European 1607/6728 2980/6309 1 0* 
Erdmann J 2009 European 1222/1298 18.2k/20.0k 2 0 
Kathiresan 2009 European 2967/3075 9746/9746 5 4 
Tregouet 2009 European 1926/2938 7073/7325 1 0 
Reilly 2011 European 1808/915 10585/6468 2 2 
Lettre 2011 African American 260/5053 621/1629 3 0 
Erdmann J 2011 European 1157/1748 7887/8244 1 0 
Aoki 2011 East Asian 194/1539 5177/6220 1 0 
Schunkert 2011 European 22.2k/64.8k 56.7k/56.7k 18 13 
C4D 2011 European/ South Asian 
8424/7268 
6996/7794 
18.0k/16.4k33
59/2828 9 10 
Wild 2011 European 2078/2953 19.4k/35.4k 1 4 
Slavin 2011 European 2000/3000 - 4 1 
Mehta 2011 European/South Asian 15.4k/15.0k 21.4k/19.1k 0 2 
Takeuchi 2011 East Asian 806/1337 3593/6335 1 2 
Dawies 2012 European 7123/6826 5211/5821 5 0 
Hager 2012 Middle Eastern 1949 2547 0 1 
Lu 2012 East Asian 1515/5019 15,5k/11.5k 4 4 
Lee 2013 East Asian 2123/3591 3052/4976 1 4 
Hirokawa 2014 East Asian 1666/3198 11.4k/28,4k 2 2 
Nikpay (CAD)~ 2015 Mixed (European) 61.3k/126.3k - 15 30 
Nikpay (MI)~ 2015 Mixed (European) 38.1k/126.3k - 8 30 
Dehghan (CAD)~ 2016 European 2406/21.6k 3059/28.1k 1 1 
Dehghan (MI)~ 2016 Mixed (European) 1570/21.6k 2874/4.9k 3 1 
Wakil 2016 Middle Eastern 2563/2266 503/371 7 11 
CAD – coronary artery disease, WTCCC – Wellcome Trust Case Control Consortium, k – 
thousands, C4D – Coronary Artery Disease Genetics Consortium, MI – myocardial infarction, 
* three initial CAD GWAS studies reported 9p21.3 locus at the same time. ~reported CAD 
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and MI as separate endpoints. Comprehensive CAD GWAS summary can be found in 
Supplementary 5. 
One of the earliest and most consistently replicated across multiple populations is 9p21 
locus, associated with CAD or MI in more than ten populations and counting (Supplementary 
5). Latest CAD GWAS are focused on meta-analysis of many studies and therefore have 
increased in size significantly. If sample size in 2005-2008 were 1000 to about 4500 for cases, 
then latest meta-analyses are using over 60 000 cases and 120 000 controls (Table 3) 
(MacArthur et al. 2017, Nikpay et al. 2015). That has had great effect on study power and 
ability to discover ever smaller effects on development of CAD. Early associations had OR 
range about 1.20-2.10 per SNP. One of latest studies are reporting ten novel variants 
associated with CAD with OR ranging from 1.06 to 1.20 under additive model (Nikpay et al. 
2015). Same authors report interesting and by nowadays standards strong association (OR 
1.5) of SNP rs12976411 located in chr19 non-coding RNA (LOC400684) protecting from CAD 
under recessive model, but no association under additive model (Nikpay et al. 2015). This 
way of testing CAD risk is certainly underreported and hard to estimate what % of studies 
have performed such tests and not reported insignificant associations. 
Variants associated with increased CAD risk can be divided into groups based on their 
mechanism of action which contributes to development of CAD. These groups describe 
known conventional risk factors. They are LDL cholesterol, triglycerides, blood pressure, 
inflammation, plaque formation/vascular remodeling, nitric oxide/cyclic guanosine 
monophosphate signaling and large group of “others” where possible involvement in CAD 
risk increase is still unclear. 
One of prominent groups of increased genetic and also conventional risk factors of CAD is 
linked with non-optimal LDL regulation. Increased blood LDL level (above 1.8 mmol/L) is 
known CAD risk factor and lipid-lowering therapy (by using class of drugs called statins or 
HMG-CoA reductase inhibitors) is employed to prevent and or delay CAD symptomatic 
onset. LDL receptor (LDLR), encoded by LDLR found in humans at chr19p13.2 locus, is 
important regulator of LDL metabolism (Cyrus et al. 2002). LDLR in liver cells uptakes 
circulating LDL for internal use and lowers its level in the blood (Zhang et al. 2013). Also LDLR 
can recognize apoE protein from chylomicrons and very low-density lipoprotein particles 
(Schmidt et al. 2008). Dysfunctional LDLR or its regulation is often causing of familial 
hypercholesterolemia (Benlian et al. 1990, Soutar and Naoumova 2007). GWAS have 
identified LDLR variations with increased CAD risk (Bis et al. 2011, Myocardial Infarction 
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Genetics et al. 2009) and pro-atherosclerotic lipid profile (Myocardial Infarction Genetics et 
al. 2009, Sarwar et al. 2007). The T allele of rs2228671 is associated with decreased LDL 
concentration and with decreased CAD risk, while T allele of rs688 is associated with 
increased LDL concentration and mRNA splicing efficiency (Jamaldini et al. 2014). Also a 
separate study has found that rs688 is important for proper endosomal recycling of LDLR 
(Gao et al. 2013). CAD risk is also increased in carriers of rs1122608 G (more common) allele 
(Kullo and Cooper 2010, Myocardial Infarction Genetics et al. 2009, Zhang et al. 2013) OR 
2.09 (CI 0.95 1.48–2.97) ranging from OR 1.82 in combined East Asian populations to OR 2.31 
in Europeans to 3.37 in East Asian males (Liu et al. 2016). This variant is located at 58.7 
kilobases (kb) upstream of the LDLR gene. It has been associated with CAD risk under 
dominant model in European populations, but studies in East Asian populations show mixed 
results (Yang et al. 2010, Wang et al. 2014, Zhang et al. 2013) which meta-analysis attributed 
to gender difference (G allele is a risk factor for East Asian men, but not women) (Liu et al. 
2016). At least two studies have reported LDLR association with CAD independently from 
lipid profile of the patients (Jamaldini et al. 2014, Martinelli et al. 2010).  
One of the mechanisms of variations associated with CAD risk involves triglycerides and 
multiple variations in different genes and is centered around enzyme lipoprotein lipase (LPL). 
LPL reduces triglyceride level in the blood by hydrolyzing lipoprotein-bound triglycerides. Its 
activity is upregulated by apolipoprotein A-V (APOA5), but reduced by apolipoprotein C-III 
(APOC3) and angiopoietin-like 4 (ANGPTL4). Variants in genes of these proteins have been 
associated with CAD in GWAS. Missense variant (p.D36N; minor-allele frequency, 1.9%) in 
LPL leads to 20% reduced enzyme activity and is associated with increased CAD risk 
(Myocardial Infarction et al. 2016). ANGPTL4 missense variation p.E40K leads to inactive 
ANGPTL4 (negative LPL regulator) and is cardio-protective due to significantly reduced 
triglyceride levels while not influencing LDL or high-density lipoprotein (Myocardial 
Infarction et al. 2016). At the same time mutations in positive LPL regulator APOA5 increases 
plasma triglycerides and risk of CAD (Do et al. 2015). And in line with ANGPTL4 negative LPL 
regulator’s APOC3 loss of function variants also are cardio protective (Tg et al. 2014). This 
detailed knowledge (Figure 3) of inner regulation of LPL system has led to the identification  
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of novel drug targets and APOC3 inhibitors are already in development and clinical trials (see 
chapter 1.6). 
Figure 3. Regulation of blood triglyceride level by LPL and its regulators (Kessler et al. 2016).  
 
9p21 deserves special mention due to world-wide reproduction of association results and 
puzzling role of this locus how DNA variations are translated into pathophysiology. 
Association of 9p21 with CAD and MI was discovered in 2007 by four independent research 
groups (Helgadottir et al. 2007, McPherson et al. 2007, Samani et al. 2007, Wellcome Trust 
Case Control et al. 2007). Risk allele homozygotes had observed CAD OR from 1.20 to 1.37 
(CI 0.95 1.02-1.58) in three studies (McPherson et al. 2007, Samani et al. 2007, Wellcome 
Trust Case Control et al. 2007) and MI OR 2.02 (CI 0.95 1.72-2.36) in the fourth (Helgadottir 
et al. 2007). The locus is 58kb in size and multiple strong association signals have been 
observed (Helgadottir et al. 2007, McPherson et al. 2007, Samani et al. 2007, Wellcome 
Trust Case Control et al. 2007). Follow up studies and meta analyses confirmed the 
association in various populations (Cakmak et al. 2015, Chan et al. 2011, Cheng et al. 2011, 
Foroughmand et al. 2015, Kumar et al. 2011, Meng et al. 2008, Nawaz et al. 2015). Also 
associations with various other cardiovascular conditions (Yamagishi et al. 2009, Niemiec et 
al. 2017, van 't Hof et al. 2016) as well as diabetes (Cheng et al. 2011, Cugino et al. 2012) and 
cancers have been reported (Li et al. 2014, Merlo et al. 1994). Fine mapping of the region 
was unable to pinpoint causal mutation (Congrains et al. 2012). Nearest genes are at least 
90kb away and are known tumor suppressors CDKN2B and CDKN2A (Cunnington and 
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Keavney 2011). Also main association cluster is next to long non-coding RNA, ANRIL, which 
has multiple transcripts and CAD associated variants could alter its expression. For some 
time ANRIL was the main suspect of CAD causality (Congrains et al. 2013, Pasmant et al. 
2011)until allelic imbalance and expression quantitative trait loci studies showed that 9p21 
contains enhancers which are the main regulators of CDNK2B, CDNK2A and MTAP 
expression. That would mean that all genes in this locus contribute to CAD susceptibility 
(Cunnington et al. 2010, Liu et al. 2009, Motterle et al. 2012), but several studies have failed 
to replicate finding and leaving question open to debate and new research (Congrains et al. 
2012, Holdt et al. 2011, Jarinova et al. 2009, Pilbrow et al. 2012). ANRIL is conserved among 
primates, but not in mice hampering to understand its role in CAD (Jarinova et al. 2009) but 
when 9p21 homology locus were deleted in inducible knockout mice model, expression of 
both Cdkn2a and Cdkn2b were decreased supporting hypothesis of enhancer region at 9p21 
(Visel et al. 2010). 
GWAS discoveries have led to expansion of computational genomic methods in order to 
untangle complexity of CAD risk factors. Gene-gene, gene-environment interactions as well 
as epistasis between multiple alleles may be responsible for non-linear increase in CAD risk 
allowing for “missing heritability” to exist even within already discovered susceptibility 
variations (Nikpay et al. 2015, Zuk et al. 2012). Also integration of disease-related data from 
functional genomics allows to reduce complexity of finding “true” causal variant (Kichaev et 
al. 2014, Trynka et al. 2015). Bayesian networks can be used in key driver analysis to find 
driver genes in CAD (Makinen et al. 2014) and together with protein-protein interaction and 
co-expression data Bayesian networks have identified TNFRSF13C and EBF1 as CAD 
susceptibility genes (Huan et al. 2013). Also, in case of 9p21, chromosome conformation 
capture method was used to investigate pairwise interactions between CDKN2B, CDKN2A, 
MTAP and INF2A and it was discovered that interactions were modulated by INFγ 
(Harismendy et al. 2011). 
Additionally, whole exome sequencing in high risk individuals and confirmed healthy 
controls have shown possibility to identify rare variants protecting coronary arteries from 
formation of plaques (Abramowitz et al. 2016).  
These examples demonstrate that integration of data from various biological levels (genetic 
from GWAS or whole exome sequencing or whole genome sequencing, epigenetic, 
transcriptomic and proteomic) can lead to more complete picture of a complex system 
(Hawkins et al. 2010, Kwon et al. 2012). 
29 
 
1.2.12. CAD genetic risk and its use in clinical setting 
Latest trend in GWAS data use is increasing precision of risk scoring for patients. After initial 
excitement “GWAS: key to personalized medicine” ended, several studies were negative 
about possibility to use such data to increase resolution of patient classification (de Haan et 
al. 2012, Ripatti et al. 2010). Nevertheless, seven out of 17 studies using genetic variants 
associated with CAD, found statistically significant increase in risk prediction (AUC increase 
when including genetic information). Nine studies observed non-significant AUC increase in 
their analysis (Muller et al. 2016). Amount of AUC increase can be called modest at best 
ranging from 0.001 (Tikkanen et al. 2013) to 0.07 (Bolton et al. 2013). Yet for global 
healthcare that would mean thousands of people saved because of improved risk prediction 
and improved targeted treatment (Tikkanen et al. 2013). Since nowadays the whole genome 
genotyping cost is getting comparable to some biochemical analyses of the blood, it offers 
good cost-benefit ratio to be performed. 
For some groups of patients’ inclusion information of genetic variations in risk calculation is 
more beneficial than for others. For example, in group of middle aged men have shown 
greatest risk prediction improvement in at least two studies (de Vries et al. 2015, Hughes et 
al. 2012). Also it seems that calculating weight for each variation is important as studies 
performing such calculation have higher improvements in patient discrimination and 
reclassification (Ganna et al. 2013). Also using genetic variations that are not associated with 
intermediate phenotypes of traditional risk factors but directly to CAD increase clinical value 
of risk prediction especially for individuals with intermediate risk (Lluis-Ganella et al. 2012). 
Inclusion of genetic information in primary CAD prevention in patients at medium risk would 
avert one CAD event for every 300-400 participants of the screening. That translates to 3.15 
(CI 0.95 -1.30-7.60) CAD event free years per 1000 people of general population (Ganna et 
al. 2013). But study involving South Asian population failed to find link between genetic risk 
score and CAD events and reclassification. Although study design and sample size issues 
were mentioned main suggestion were that different set of CAD risk variations may be 
required for accurate risk prediction in the South Asian population (Beaney et al. 2015). 
Probably genetic risk factors should be determined using population of similar ancestry, but 
most of current genetic CAD risk factors are discovered in studies using populations of 
European descent (Supplementary 5).  
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1.2.13. Drug targets trials due to CAD genetics studies 
Inhibition of APOC3 by RNA interference-mediated knockdown is currently being 
investigated in clinical trials. In a dose-ranging phase II study, ISIS 304801, an antisense 
APOC3 inhibitor, led to a dose-dependent 31–71% reduction in triglycerides (Gaudet et al. 
2015). 
Currently investigated PCSK9 inhibitors exploit monoclonal antibodies to inhibit the  
effect of PCSK9 in the circulation. Also RNA interference- and small molecule-based 
approaches are in the development and evaluation (Fitzgerald et al. 2014, Robinson et al. 
2015). 
The development of so-called precision medicine is a major goal of current CAD funding 
concepts (Jameson and Longo 2015). Unfortunately, there is currently only limited evidence 
to suggest that genetic testing of individual common risk variants allows for stratification 
into different treatment modalities. Exception however are individuals with a high genetic 
risk score who appear to have a larger benefit from statin treatment than those with low 
genetic risk (Hughes et al. 2012, Mega et al. 2015, Schunkert and Samani 2015). 
1.2.14. Adenosine system and CAD 
Adenosine receptors (AR) are a group of four known G protein-coupled receptors enabling 
adenosine signaling within an organism. Their molecular structure is similar to other G 
protein-coupled receptors with seven α-helical transmembrane domains and an extracellular 
amino-terminus and an intracellular carboxyl-terminus (Fredholm et al. 2011). 
Adenosine is purine nucleoside primarily used in modified form to store genetic information 
and as energy exchange molecule in all living cells. Additional important role of adenosine is 
signaling and coordination of processes within body. It is produced from metabolism of 
adenosine triphosphate (ATP) (Okada et al. 2006, Picher et al. 2003, Robson et al. 2005) and 
have range of functions carried out via four types of adenosine receptors (A1R, A2AR, A2BR 
and A3R) (Fredholm et al. 2011). 
Functions of ARs are: modulation of neurotransmitter release (Sebastiao and Ribeiro 2000), 
synaptic plasticity (Costenla et al. 2001) and neuroprotection in ischemic, hypoxic and 
oxidative stress events (Cunha 2001, Ferreira and Paes-de-Carvalho 2001). 
Adenosine produces either vasoconstriction or vasodilation of veins and arteries (Li et al. 
1998). Adenosine regulates T cell proliferation and cytokine production (Hasko and Pacher 
2008). The nucleoside also inhibits lipolysis and stimulates bronchoconstriction (Van der 
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Graaf et al. 1999). Reports in 2016 also highlight its role as non-narcotic analgesic agent 
(Janes et al. 2016). 
ARs are classified based on their interaction with adenylyl cyclase to regulate cyclic 
adenosine monophosphate production. The A1R and A3R are coupled to Gi/o protein and 
reduce activity of adenylyl cyclase (Cunha 2001, Fredholm et al. 2011, Paes-De-Carvalho 
2002), but A2AR and A2BR are coupled to Gs/olf (Fredholm et al. 2011) and enhance cyclic 
adenosine monophosphate production. 
A3R is located on chromosome 1 at p13.2 locus. It spans 4.33kb and most transcripts contain 
one intron (Yates et al. 2016). 
A3R is mostly studied due to its protective action in cardiac ischemia. Several studies have 
shown that the A3R is important mediator of cardioprotection during and following 
ischemia-reperfusion (Headrick and Peart 2005). 
There is no agreement how exactly A3AR cardioprotection timing works. A number of 
studies have indicated that pre ischemic activation of A3R is necessary or crucial (Black et al. 
2002), but others have argued that main protection is post ischemia (Jordan et al. 1999, 
Maddock et al. 2002, Suleiman et al. 2001), and also there is articles stating that A3R 
agonism is cardioprotective with either pre- or post-ischemic treatment (Headrick and Peart 
2005). In animal models suggested injury inducers are neutrophils, whose activation is 
reduced upon A3R agonist administration (Jordan et al. 1999). Molecular mechanism also is 
suggested as A3R induced blockade of mitochondrial permeability transition pore (mPTP) 
opening, because studies state that mPTP opening is crucial for the ischemia-reperfusion 
injury to develop (Suleiman et al. 2001, Weiss et al. 2003). Also a study has reported A3AR 
activation causes activation of PI3K/Akt pathway which in turn inhibits glycogen synthase 
with following blockage of mPTP opening (Park et al. 2006). 
In line with cardiovascular epidemiology and cardioprotection by A3R Ashton et al. has 
reported decreased mRNA of A3R and increased mRNA of A2BR when aging (Ashton et al. 
2003). Also decreased amount of A1R has been observed in aged hearts during ischemia 
which leads to hypothesis that both decreased A1R and A3AR expression is responsible for 
different results in cardioprotection timing (Borea et al. 2009). This hypothesis is expanded 
in a review that all AR subtypes are involved in cardioprotection, but with different types of 
cordioprotective modulation and differently during aging and with interplay between each 
of them (Nishat et al. 2016, Philipp et al. 2006, Solenkova et al. 2006). 
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1.3 Glyoxalase system in Diabetes mellitus complications  
1.3.1. Glycation, methylglyoxal and glyoxalase system 
The glyoxalase system with its rate limiting enzyme glyoxalase 1 (GLO1, Enzyme Commission 
4.4.1.5.) protects living cells from production and accumulation of advanced glycation end 
products (AGEs) which are damaging to life-enabling metabolic processes.  
GLO1 was discovered in 1913 (Dakin 1913) and more than 100 years of research has 
provided insight about its critical role in almost all life forms. 
The main contributor towards creation of AGEs is a byproduct of glycolysis and other 
metabolic reactions a toxic compound called methylglyoxal (MG). Other reactive molecules 
such as glyoxal and 3-deoxyglucosone are minor contributors.  
Glucose is main source of energy for the cells. But not all glucose molecules can successfully 
finish energy production process and some of them forms MG (Phillips and Thornalley 1993). 
Because glycolysis is occurring in all cells, MG is created in both normal and pathological 
conditions. 
Both enzymatic and non-enzymatic reactions produce MG and it forms at various speeds in 
various organisms, tissues, cells under different physiological conditions (Thornalley 1996). 
MG formation via the fragmentation of the triosephosphates glyceraldehyde-3-phosphate 
and dihydroxyacetone phosphate was discovered in 1993 (Richard 1993). 
Up to 0.4% of glycosis molecules in energy metabolism result in MG production (Kalapos 
2008). And is elevated when concentrations of precursors of MG are high, as in 
hyperglycemia, impaired glucose utilization and triosephosphate isomerase deﬁciency 
(Ahmed et al. 2003). Half-life of MG is short in a biological environment (Kalapos 2008) and it 
readily reacts with lipids, nucleic acids and with lysine and arginine residues of proteins to 
form AGEs (Rabbani and Thornalley 2012, Thornalley 2005, Thornalley 2007). 
GLO1 of glyoxalase system is the main enzymatic metabolizer of MG and glyoxal (Thornalley 
1993). Glyoxalase system together with aldoketo reductases (AKRs) and aldehyde 
dehydrogenases (ADHs) metabolizes more than 99% of MG providing efficient defense 
mechanism against formation of AGEs. With the exception of renal medulla GLO1 is more 
than 30 fold more active than AKRs and ADH (Rabbani et al. 2016). GLO1 is both efficient and 
abundant enzyme in the human cells amounting up to 0.02% of the total protein (Larsen et 
al. 1985). It is known that GLO1 does not metabolize 3DG and its removal is mostly carried 
out by AKRs and ADHs (Collard et al. 2007). 
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Detoxification of MG is a three step process. At first reduced glutathione (GSH) reacts with 
MG in non-enzymatic reaction forming hemithioacetal which is further converted by GLO1 to 
S-D-lactoylglutathione. Hydroxyacylglutathione hydrolase converts this compound to D-
lactate and recycles GSH (Figure 4) (Thornalley 1993).  
 
Figure 4. Methylglyoxal detoxification pathway by glyoxalase I and hydroxyacylglutathione 
hydrolase. 
S-D-lactoylglutathione is nontoxic therefore its creation by GLO1 is crucial step for MG 
detoxification. It can be concluded that GLO1 activity indirectly determines MG toxicity to 
the cell and amount of AGEs formed. It must be noted that GSH recycling occurs in the last 
reaction and high amount of MG or low activity of hydroxyacylglutathione hydrolase can 
lead to GSH deficiency for other cell processes (Dringen 2000).  
Glyoxalase system is ubiquitous to almost all organisms (except certain protozoa (Sousa Silva 
et al. 2012)). It is located in cytosol and mitochondria (Thornalley 1990). 
Toxicity of MG can be understood and importance of GLO1 can be appreciated when looking 
on effects of AGEs within cell and whole organism. AGEs are implicated in wide range of 
pathophysiological processes like ageing (Ahmed et al. 2003, Morcos et al. 2008), vascular 
remodeling (Hanssen et al. 2014), Alzheimer’s disease (Angeloni et al. 2014), autism (Maher 
2012), hyperalgesia (Koivisto et al. 2014), inflammation (Tikellis et al. 2014) and most 
notably diabetes and its complications (nephropathy (Rabbani et al. 2007), neuropathy 
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(Bierhaus et al. 2012, Skapare et al. 2013) and retinopathy (Berner et al. 2012, Miller et al. 
2010)). Mechanism how these pathological phenotypes arise from changes in molecules is 
not always clear although molecular workings and reaction chains within cells are well 
described. 
MG induced glycation often forms complex and stable adducts (Lo et al. 1994). These are 
known as Maillard reactions and start with formation of Shiff’s base adduct when MG reacts 
with lysine and arginine side chains of the protein (Padayatti et al. 2001). Typical AGE that 
forms this way is argpyrimidine, compound with a suspected role in apoptosis (Antognelli et 
al. 2014, Sakamoto et al. 2002). Common occurrence is modification of blood serum proteins 
under normal physiological MG concentrations, but chronically elevated MG levels leads to 
irreversible change in protein structure. Long lived proteins are at the most risk to form 
AGEs. MG readily glycates albumin, hemoglobin, mitochondrial proteins and transcription 
factors (Lo et al. 1994, Rabbani and Thornalley 2012). Accumulation of AGEs increases with 
age resulting in widespread protein damage. MG not only directly influence protein function 
by amino acid modifications but also these modified proteins interact with AGE receptors 
(Grillo and Colombatto 2008). Such interaction switches on inflammatory response adding to 
damage done by MG. It has been shown that MG increase levels of free radicals in dose 
dependent manner and initiates production of pro-inflammatory factors (TNFα, IL-6 and IL-8) 
(Desai et al. 2010). 
Glycation of DNA by MG also has been observed especially for adenine and guanine bases 
(Thornalley 1996). Not only nucleotide AGE formation causes multibase deletions and 
substitutions (Murata-Kamiya et al. 2000) but also multipolymer crosslinking (DNA-DNA, 
DNA-protein, protein protein)(Murata-Kamiya and Kamiya 2001, Tu et al. 2013) which could 
be mechanism behind DNA replication inhibition by MG (Kalapos 1994). 
Similar to many proteins, GLO1 activity is regulated both by expression and by modification 
after translation. The first exon of GLO1 contains antioxidant-response element (ARE) (Xue 
et al. 2012) which negatively affects GLO1 expression when hypoxia inducible factor 1α 
HIF1α binds to it (under hypoxia) (Zhang et al. 2012). Also erythroid 2-related factor 2 (Nrf2) 
decreases GLO1 expression as a stress response (Xue et al. 2012). Nrf2 itself is suppressed by 
nuclear factor kappa-light-chain-enhancer of activated B cells in diabetes, metabolic 
syndrome and obesity due to chronic hyperglycaemia and inflammation (Bierhaus et al. 
2001, Liu et al. 2008). Other regulatory elements in GLO1 are MRE (metal-response 
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element), IRE (insulin-response element), E2F4 (early gene 2 factor isoform 4), and AP-2α 
(activating enhancer-binding protein 2α) (Rabbani et al. 2014). 
1.3.2. Glyoxalase system in diabetes complications 
Hampered GLO1 activity in diabetic conditions (Bierhaus et al. 2001, Liu et al. 2008)is part of 
the reason why microvascular complications (nephropathy, retinopathy and neuropathy) are 
developing in most of the diabetic individuals (Feldman 2003) (McLellan et al. 1994, Ratliff et 
al. 1996, Thornalley et al. 1989). It has been shown that GLO1 activity is decreased and 
protein derived AGEs concentration is increased in renal, retinal and neural models of blood 
vessel complications (Barati et al. 2007, Bierhaus et al. 2012, Karachalias et al. 2010, Miller et 
al. 2010, Palsamy and Subramanian 2011). Cell cultures of vascular endothelial cells in high 
glucose environment show elevated dicarbonyl stress from increased MG concentration 
(Dobler et al. 2006). 
Diabetic retinopathy is mostly caused by damages to blood vessels of the retina and is the 
main cause of adult blindness in the US. Nine out of ten diabetics have some form of 
retinopathy within 15 years after diagnosis. Diabetes causes 25 000 cases of blindness a year 
in the US (Fong et al. 2003, Gardner et al. 2002). MG increase has been detected in diabetic 
kidney (Geoffrion et al. 2014). Diabetic nephropathy accounts for 40% of new kidney failure 
diagnoses (Skyler 2001). Neuropathy and painful neuropathy are common long term diabetic 
complications with critical impact on quality of life of the patient. Painful neuropathy occurs 
around 10% of cases and pathophysiology is unclear and symptoms often cannot be treated 
with nonsteroidal anti-inflammatory drugs or opiates (Calcutt 2002). MG concentration in 
plasma is increased in type 2 diabetes (T2D) patients with painful neuropathy. These findings 
were strengthened by results in animal model that MG can induce primary hyperalgesia 
showing potential reason of painful diabetic neuropathy (Bierhaus et al. 2012). Activity of 
GLO1 was significantly negatively correlated (r = − 0.261, p = 0.007) with duraƟon of T1D and 
was reduced in patients of both types of diabetes with severe painful neuropathy compared 
to individuals with mild or moderate symptoms (Skapare et al. 2013). Most of non-traumatic 
amputations are caused by diabetic neuropathy. (Feldman 2003)and lifetime risk of 
amputation for diabetic is around 15% (Feldman 2001). Diminished MG detoxification and 
following oxidative stress in the microvasculature is significant factor leading to 
complications in diabetes (Obrosova 2003). 
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Blood MG concentration was increased up to 5-6 fold in case of diabetes patients (McLellan 
et al. 1994). Elevated concentration of AGEs in plasma proteins and skin collagen in diabetics 
was associated with higher risk of vascular complications (Ahmed et al. 2005, Hanssen et al. 
2015) including CAD in diabetes (Hanssen et al. 2015, Nin et al. 2011).  
A study suggests role of MG and AGEs (therefore weaker GLO1) in development of T1D by 
poor protection of beta cells (Kim et al. 2013). Another studies point towards dicarbonyl 
stress as promoter of insulin resistance leading to T2D (Maessen 2014, Nigro et al. 2014). 
Together with the fact that GLO1 activity is decreased in hyperglycemia these observations 
and knowledge about GLO1 regulation have led to idea to treat diabetes with GLO1 
expression inducers activating Nrf2 (Xue et al. 2012). One such activator currently is in phase 
2 clinical trial to assess its potential in treating diabetic nephropathy as well as other 
microvascular complications of diabetes and cardiovascular disease (Xue et al. 2016). 
1.3.3. Genetics of glyoxalase system in diabetes and other conditions 
Gene encoding GLO1 is located in human 6th chromosome at p21.2 locus, spans 27.22kb 
and has only two transcripts. Other member of glyoxalase system HAGH 
(hydroxyacylglutathione hydrolase) is located at 16p13.3 and spans 31.57 kb on the reverses 
strand of DNA (Yates et al. 2016). 
Genomic polymorphisms in HAGH are rare. Six SNP with global minor allele frequency (MAF) 
above 1% are known (as of April 2017). Five of them are synonymous and one missense 
without known phenotype alteration. Only two are present in population with European 
descent where also population of Latvia belongs (Yates et al. 2016). 
Two relatively common (global MAF above 20%) GLO1 SNP are known and present in human 
populations worldwide. There are also studies published about these associating GLO1 SNP 
with increased prevalence of diabetic neuropathy (Groener et al. 2013), cardiovascular 
complications (Rabbani and Thornalley 2011) and autism (Barua et al. 2011). The most 
studied is adenosine to cytosine exchange in base 419 in exon 4 of GLO1 (rs4746 also known 
as rs2736654). It is missense SNP where Ala111 is substituted with glutamic acid. Proteomic 
study discovered that GLO1 with glutamic acid has lower activity and higher acidity than wild 
type protein (Junaid et al. 2004). This was confirmed in a study by Barua et al. who found 
reduced activity of enzyme, elevation of MG and RAGE in patients with autism (Barua et al. 
2011) and a study which found significantly higher rate of cardiovascular disease and 
peripheral vascular disease in patients requiring hemodialysis (Kalousova et al. 2008) . 
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Meanwhile, Dutch study found no association of rs4746 and other eight GLO1 
polymorphisms with vascular complications in T2D patients (Engelen et al. 2009). 
It was found that rs4746 allele frequency is not in Hardy-Weinberg equilibrium in patients 
with Alzheimer’s disease, but no significant association was found (Chen et al. 2004). 
Investigation into whether rs4746 carriers have increased enzyme activity in T1D patients 
with normal renal activity lead to conclusions that there is no significant association as well 
as no association with serum glucose, glycated hemoglobin and AGEs levels (Sakhi et al. 
2013). 
Literature is sparse about other GLO1 polymorphisms. SNP rs1049346 in GLO1 promoter 
(but not rs4746) was associated with diabetic retinopathy and nephropathy in Chinese T2D 
patients (Wu et al. 2011). 
It is known that GLO1 is located in region with copy number variation in approximately 2% of 
humans. This causes 2-4-fold increase in GLO1 expression, but there is no study published 
with assessment if these individuals are more protected from formation of AGEs and/or 
diabetic complications (Cahan et al. 2009, Redon et al. 2006). 
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1.4 Pituitary adenomas 
1.4.1. Pituitary location, anatomy and functions, embryonal development 
Pituitary is an endocrine gland located in human head at the base of brain. Superior to 
sphenoid bone in a cavity called sella turcica and below chiasma and hypothalamus. Pituitary 
is connected to hypothalamus via pituitary stalk through which blood supply is organized 
and control from hypothalamus is executed. Pituitary consists of three lobes 
adenohypophysis (pars anterior, anterior lobe), neurohyphophysis (pars posterior, posterior 
lobe) and pars intermedia (intermediate lobe) which is rudimentary in adult humans. Each of 
the lobes has separate development and functions (Graaff 2001).  
Organogenesis of pituitary begins at 4th week of embryogenesis and can be described as 
three stage process. First initiation of organogenesis and Ratke’s pouch occurs, after which 
evagination of Rathke’s pouch and cell proliferation follows and the last stage of pituitary 
organogenesis is cell lineage determination and cellular differentiation. Briefly at closer look 
pituitary develops from fusion of two types of ectoderm. Adenohypophysis starts from a 
thickening of cells in the oral ectoderm (which is of epithelial origin and forms early roof of 
the mouth) and formation of hypophyseal placode which grows towards neural ectoderm to 
become Rathke’s pouch. At the same time ventral diencephalon (ectoderm of neural origin) 
forms extension growing downwards toward Rathke’s pouch, connecting with it and forming 
pituitary. Rathke’s pouch separates from oral ectoderm at week six to eight. Then cells of 
anterior wall of Rathke’s pouch proliferates and develops adenohypophysis, posterior wall 
divides slowly and give rise to pars intermedia. Cells from ventral diencephalon form 
neurohyphophysis. Final patterning and differentiation of adenohypophysis cells forms the 
five main specialized cell types of the pituitary. Given the nature of pituitary organogenesis, 
precise coordination and regulation at both locations is crucial for formation of pituitary and 
correct differentiation of hormone-producing cell types (Larkin and Ansorge 2000) Mutations 
in key developmental genes can lead to various developmental disorders (Davis et al. 2010, 
Kelberman et al. 2009, Zhu et al. 2007).  
Hormones produced and secreted by adenohypophysis are: human growth hormone (GH or 
growth hormone), regulated by growth hormone-releasing hormone and somatostatin, 
thyroid-stimulating hormone (TSH) regulated by thyrotropin-releasing hormone and 
somatostatin, luteinizing hormone and follicle-stimulating hormone regulated by 
gonadotropin-releasing hormone, corticotropins – peptide hormones (adrenocorticotropic 
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hormone (ACTH), melanocyte stimulating hormone and β-endorphin) produced after 
processing precursor proopiomelanocortin and are regulated by corticotropin-releasing 
hormone and prolactin (PRL) which is released after signal from several factors (including 
thyrotropin-releasing hormone, oxytocin, vasopressin, vasoactive intestinal peptide, 
angiotensin II, neuropeptide Y, galanin and neurotensin) depending on situation. PRL release 
is downregulated by dopamine. Adenohypophysis is regulated by hypothalamus via 
previously mentioned release hormones that are secreted in adenohypophysis and delivered 
there by capillaries forming hypothalamic-hypophysial portal system (Institute for Quality 
and Efficiency in Health Care 2015). 
Intermediate lobe produces and secretes melanocytes stimulating hormone. Posterior lobe 
of pituitary does not produce hormones, but stores and releases hormones (antidiuretic 
hormone (vasopressin) and oxytocin) produced by magnocellular neurosecretory cells of 
hypothalamus into the bloodstream (Institute for Quality and Efficiency in Health Care 2015). 
1.4.2. Incidence of pituitary adenomas 
PA are neoplasms (new and abnormal growth of tissues) of the pituitary with benign 
characteristics. Up to 15% of clinically active intracranial neoplasms are PA (Jagannathan et 
al. 2005). Prevalence of PA are high with different samples showing range from 1.5% up to 
27% in general population (Molitch 2009) with meta-analysis estimation of prevalence 
standing at 16.7% (Ezzat et al. 2004). Clinically significant adenomas are much rarer ocasion 
one in 1000 to 1300 individuals (Daly et al. 2006, Fernandez et al. 2010) although there are 
reports of prevalence up to one PA in 200 individuals (Rosario 2011). Incidence of PA stands 
between 0.22 to 8.2 new PA cases per 100,000 per year ((Monson 2000) after Gold 1981). PA 
is age related with significant increase of cases and incidence after age of 45 ((Monson 2000) 
after Gold 1981). PA is associated with female sex, epidemiological data show that 
approximately 2/3 of PA occur in females (Gruppetta et al. 2013, Monson 2000) (prevalence 
males 46/100,000 and females 105/100,000 (Gruppetta et al. 2013). 
1.4.3. Types of pituitary adenoma 
PA are usually classified either by size, extension or function according to the aim of the 
classification. Hardy classification use four grades to describe PA by their size <10mm (grade 
I), >10mm within sella (grade II), >10mm outside sella (grade III) and large adenomas with 
invasion in surrounding tissue, including but not limited bone, brain, compression of optical 
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nerve (grade IV) (Hardy 1969). Also PA are more informally categorised by their size into two 
groups: microadenomas (less than 10mm in diameter) and macroadenomas (more than 
10mm). This classification seems to originate from requirements of surgery and origin is lost 
in time.  
Classification by extension focuses on invasive PA which is described in details at Micko et al 
and in brief, uses intracavernous and supracavernous internal carotid arteries as a reference 
(Micko et al. 2015).  
Functional classification uses disruptions in patients hormonal profile to classify PA. Between 
35-40% of PA are non-functional (NFPA, does not secrete hormones, to cause detectable 
hormonal change) and other 60-65% are hormones secreting PA. Most common functional 
adenoamas are prolactinomas (accounting for around 40% of all PA), followed by growth 
hormone (GH) secreting PA (~13%)(often leading to acromegaly), ACTH secreting PA 
(~8,5%)(causing Kushing’s disease) and TSH secreting and others, including mixed PA 
(~1%)(Famini et al. 2011). Table 4. Also morphological classification is used for some 
secretory types of adenomas (Syro et al. 2015), especially detailed it is developed in 
somatotropinomas leading to acromegaly.(Cuevas-Ramos et al. 2015). 
Upcoming PA classification by World Health Organisation is set to be published in 2017 
based on subclassification with pituitary transcription factors (Shaid and Korbonits 2017). 
Table 4. Frequency of PA types among all patients, sex and ages. (Famini et al. 2011). 
Diagnose Total N 
N Age range (average) 
Males Females Males Females 
Prolactinoma 395 90 305 17-81 (46) 15-89 (36) 
NFPA 364 162 202 18-85 (54) 17-87 (47) 
GH adenoma 127 59 68 19-84 (49) 18-82 (45) 
ACTH adenoma 84 18 66 19-77 (43) 10-66 (38) 
GH/PRL mixed 4 3 1 24-42 (32) 15 
Nelson’s syndrome 2 0 2 - 44-66 (50) 
Pituitary carcinoma 2 2 0 45-75 (60) - 
Luteinizing hormone/follicle-
stimulating hormone adenoma 1 1 0 59 - 
GH/TSH mixed adenoma 1 0 1 - 31 
TSH adenoma 1 0 1 - 55 
N – number of patients, NFPA - non-functional pituitary adenoma, GH – growth hormone, ACTH - 
adrenocorticotropic hormone, PRL - prolactin, TSH - thyroid-stimulating hormone. 
1.4.4. Genetics of pituitary adenomas 
Both genetic and epigenetic factors are involved in development of PA (Peltomaki 2012). Yet 
majority of PA genetic background remains undiscovered. PA are thought to be of 
monoclonal origin (Jacoby et al. 1990). Current literature suggest that up to 95% of PA are 
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sporadic where somatic mutations, mosaic mutations, and familial low penetrance 
mutations are the cause of neoplasm (Shaid and Korbonits 2017). Another studies show that 
clinically significant adenomas tend to occur in families (Couldwell and Cannon-Albright 
2010) and syndromic disease, positive family history, childhood-onset adenomas are the 
most important risk factors for prediction of PA (Shaid and Korbonits 2017).  
1.4.5. Genetics of sporadic pituitary adenoma 
Sporadic PA account for about 95% of pa cases. Over time mutations in several genes have 
been found to contribute towards PA in specific or broader range of cases. Heterogeneity of 
causes is the reason why PA can be considered fully multifactorial disease (Zhou et al. 2014). 
GNAS is located at chr20 q13.32 locus on the forward strand. It spans 71,47kb and at least 58 
transcripts have been detected (Yates et al. 2016). This gene encodes G protein α subunit 
and mutation can nullify or greatly diminish GTP-ase activity of the α subunit and it becomes 
constitutively active (permanently switched on). Then, through increased production of 
cyclic adenosine monophosphate and its dependent PKA, which ensures binding of CREB to 
the PIT1 promoter regions, GH synthesis increases and cell proliferation follows (Shaid and 
Korbonits 2017). Two common GNAS mutations are p.R201C/S/H and p.Q227L/R (Freda et 
al. 2007, Landis et al. 1989, Patten et al. 1990). Former accounting for majority of cases – 
89% (N=8) (Taboada et al. 2009) and 95% (N=21)(Shi et al. 1998) while latter was found in 
one case in each of these studies. GNAS mutation p.R201C has been reported in one 
corticotropinoma (Riminucci et al. 2002) and one NFPA (Taboada et al. 2009). 
Some studies report that 40% of somatotropinomas harbor somatic mutations in GNAS 
(Freda et al. 2007, Landis et al. 1989). Other studies in different population put this number 
at around 15% (Ronchi et al. 2016, Taboada et al. 2009). 
USP8 (ubiquitin specific peptidase 8) is located at 15q21.2 on forward strand spanning 
90.04kb (Yates et al. 2016). Nineteen transcripts encode at least seven proteins ranging from 
62 to 1118 amino acids. USP8 encodes enzyme ubiquitin carboxyl-terminal hydrolase 8 
which removes ubiquitin from other proteins, yet is also capable of promoting receptor 
degradation and is involved in protein “sorting machinery” within a cell (Berlin et al. 2010). 
Mutations in USP8 were identified in four out of ten corticotroph adenomas during exome 
sequencing. Mutations increase activity of the enzyme and increased amounts of various 
proteins, especially epithelial growth factor (EGF) receptor (Reincke et al. 2015). Increased 
EGF signaling leads to increased cell proliferation (Normanno et al. 2006). Initial discovery 
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that USP8 mutations cause corticotroph PA has been replicated at least twice (Ma et al. 
2015, Perez-Rivas et al. 2015)and in one of replications involve East Asian population (Ma et 
al. 2015). In the first validation study 134 functioning and 11 silent corticotroph PA were 
investigated and 48 of functioning PA harbored USP8 mutations, while none of silent PA did 
(Perez-Rivas et al. 2015). The second study found 67 out of 107 PA to have USP8 mutations 
therefore suggesting higher share related to USP8 somatic mutations (Ma et al. 2015). 
Interestingly PA with USP8 mutations had higher expressions of pro-opiomelanocortin, 
SSTR5, and MGMT and were more responsive to the somatostatin analog pasireotide 
(Hayashi et al. 2016). This discovery of USP8 variations as cause of functional corticotroph PA 
have helped to identify prime target for drug therapy. 
PI3KCA is located at 3q26.32 on forward strand, spans 91.98 kb and encodes at least four 
transcripts (Yates et al. 2016). Gene encodes alpha subunit of PI3K (phosphoinositide 3-
kinase), which is integral part of the PI3K signaling pathway and important interacting factor 
with the AKT and mTOR pathway (Robbins and Hague 2015). It has been described as 
oncogene for a long time and is the most frequent oncogenic pathway in breast cancer and 
in ~30% of cases PI3KCA mutations are found (Mukohara 2015). The first study to investigate 
PI3KCA mutations in PA were published in 2009 and it was found that 8/91 invasive PA 
(8,8%) had PI3KCA mutations, while none of 262 noninvasive PA did. Similar to cancers, 
mutations were found in exons 9 and 20 of the PI3KCA gene (Lin et al. 2009). Another study 
in Brazil investigated PI3KCA mutations in 33 PA. previously reported mutations were found 
in 20th exon. Three tumors were NFPA and invasive while fourth was corticotroph 
microadenoma (Murat et al. 2012). Although size of studies is not directly comparable, 
results indicate that PI3KCA mutations might contribute to development of PA. 
Recently, several studies using whole exome and genome sequencing have been performed 
to search for novel PA causing mutations in genomic and tumor DNA pairs. Newey et al. in 
2013 sequenced exome of seven PA and blood derived DNA pairs. They found low levels of 
somatic mutations, which relates to benign nature of PA. The average mutation rate was 3.5 
per adenoma (range 1-7) and no recurrent mutated genes were found even with 24 PA 
follow-up group (Newey et al. 2013). Finnish study focused on GH secreting PA. Analysis of 
twelve adenoma and corresponding blood DNA revealed on average 129 somatic mutations 
per genome and 2.3 single nucleotide variation per exome. Only recurrent mutations were 
previously reported GNAS (at codon 201) in three cases. Several chromosome loses (in 
chromosomes 1, 6, 13, 14, 15, 16, 18, 22) were detected and one patient had complex 
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chromosome rearrangement. Five tumors had somatic mutations in genes of the Ca2+ and 
ATP pathways (Valimaki et al. 2015). A study of east Asian population took systematic 
approach of sequencing seven types of PA: 20 NFPA, 20 PRL secreting PA, 20 GH secreting 
PA, 20 ACTH secreting PA, 20 gonadotropins (including follicle stimulating hormone and 
luteinizing hormone) secreting PA, 10 TSH secreting PA, and 15 mixed PA secreting at least 
two hormones. Besides USP8 (in ACTH secreting PA), GNAS (in GH secreting and mixed 
secreting GH and other hormone) and MEN1 (in mixed PA), six other genes showed somatic 
mutations in at least two tumors (KIF5A, GRB10, NR3C1, TRIP12, SP100, IARS) providing 
insight into potential drivers of PA development in some cases. Authors also report median 
somatic mutation rate per adenoma exome which is 3.3 (range 0-13) (Song et al. 2016). Also 
a study identified heterozygous missense mutation c.4136G>T (p. Arg1379Leu) in cadherin-
related 23 (CDH23) in a family with inherited PA, gene was later screened in familial PA, 
sporadic PA and healthy controls. Results revealed that 4/12 families (33%) and 15/125 
(12%) sporadic PA patients had variants in CDH23 providing yet another candidate to 
understand PA genetics (Zhang et al. 2017).  
1.4.6. Genetics of familial pituitary adenoma 
Familial PA are described as rare and encompass about 5% of all clinically significant PA 
(Shaid and Korbonits 2017). Multiple endocrine neoplasia (MEN) type 1 is an autosomal 
dominant disease caused by mutation/s in MEN1 gene. Approximately 20-50% MEN cases 
develop PA and also adenomas in other endocrine glands (Schernthaner-Reiter et al. 2016). 
MEN1 is located at 11q13.1 on reverse strand and spanning about 7.79kb. Ten exons give 
rise to at least 16 transcripts of which 14 have been found as proteins (Yates et al. 2016). 
Most transcripts encode either 610 or 615 amino acid protein MENIN which is tumor 
suppressor which regulates promoter activity of genes controlling cell cycle and proliferation 
via interaction with histone methyltransferase complex. Which in turn changes epigenetic 
modification of histones by transfer of methyl groups to lysine and arginine residues (Hughes 
et al. 2004) PA caused by MEN can be described according to Knudson two hit hypothesis of 
tumorigenesis (Knudson 1993). The first mutation is inherited and the second is somatic 
often resulting in loss of heterozygosity of the MEN1 locus or disrupting MEN1 microRNA 
mediated expression. Almost half of cases have large deletion as a second hit, 25% have 
nonsense mutation, 15% insertion, 10% have missense mutation and few percent have splice 
site mutations (Lemos and Thakker 2008). Patients with PA caused by MEN usually have 
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more aggressive tumors, with larger size and more pronounced symptoms (Syro et al. 2012, 
Verges et al. 2002). 
Next to the MEN1 at locus 11q13.2 on the same reverse strand is located aryl hydrocarbon 
receptor interacting protein (AIP) gene (Yates et al. 2016). Heterozygous mutations in AIP 
cause autosomal dominant disorder familial isolated pituitary adenoma (FIPA) with ~20% -
60% penetrance (Igreja et al. 2010). This is an early onset disorder (before age of 30) and 
mostly presenting as GH secreting adenoma with increased invasiveness and reduced 
response to drug treatment (Shaid and Korbonits 2017, Vierimaa et al. 2006). Mutations that 
cause only partial protein product are the most common in AIP related FIPA. AIP mutations 
have been found only in 20% of FIPA patients (Leontiou et al. 2008) and other known gene 
associated with FIPA is duplicated GPR101 (Beckers et al. 2015). Rest of FIPA cases have 
unknown genetic cause. AIP R304Stop mutation have been found in Italy (Ferrau et al. 2016), 
United Kingdom (Chahal et al. 2011) and Mexico (Ramirez-Renteria et al. 2016). Expression 
of AIP has been shown to be better marker of invasiveness than widely used MKI67 (Kasuki 
Jomori de Pinho et al. 2011) and predicts response to octreotide therapy independent of 
SSTR2 expression (Kasuki et al. 2012). 
MEN type 4 is a MEN like disorder but without mutations in MEN1. About 33% of MEN type 
4 patients develop PA of all types. Using information from rat studies causal gene was 
identified CDKN1B (Pellegata et al. 2006). But it is not found in all patients (Thakker 2014). 
Mutations in CDKN1B leads to disrupted cell cycle arrest (Moller 2000). 
Carney complex (CNC) can be described as a type of MEN (Stratakis and Ball 2000). Around 
10% of patients have PA secreting either GH or PRL. The causative gene has been identified 
as PRKAR1A (by two research group independently (Casey et al. 1998, Casey et al. 2000, 
Kirschner et al. 2000)), which in case of CNC functions as classic tumor suppressor - 
mutations are associated with loss of wild-type allele in CNC tumors (loss of heterozygosity 
occurs) (Kirschner et al. 2000). Around 70% of CNC cases are familial, with rest being 
sporadic. Penetrance of PRKAR1A cause CNC is close to 100% (Stratakis et al. 2001). Early in 
the research of CNC linkage studies suggested 2p16 locus as the cause of CNC, but no 
causative gene has yet (as of 2017) been identified in this region (Stratakis et al. 1996). 
Xq26.3 duplication acrogigantism (X-LAG) was discovered in a study of early childhood 
gigantism. Thirteen patients were identified with microduplication and ten of them were 
carriers of pituitary macroadenoma with median maximum diameter 16mm. Other three 
had pituitary hyperplasia. Drug therapy was not sufficient in any of patients to achieve 
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hormonal control. The duplicated genomic segment on X chromosome was about 500 kb 
long, starting at 135,627,637 and spanning to 136,118,269 (GRCh37/hg19). Yet each patient 
had unique start and end positions of the duplication, but smallest regions of overlap for all 
patients were two and encompassed four genes CD40LG, ARHGEF6, RBMX and GPR101 
(Trivellin et al. 2014). Functional investigation of these for genes revealed that GPR101 was 
expressed up to 1000 times more in pituitaries of Xq26.3 duplication carriers compared to 
non-carriers. Other three genes were either normally expressed or not expressed at pituitary 
at all. Same study also tested 248 patients with sporadic PA and no Xq26.3 duplication was 
found, but 11 patients had a c.924G→C (p.E308D) substitution in GPR101, which was not 
found in 7600 controls (Trivellin et al. 2014). GPR101 is coding orphan G-protein–coupled 
receptor with high expression in rodent hypothalamus (Bates et al. 2006). Previously 
p.A397K mutation has been described and patented as constitutive activator of receptor in 
mice (Lowell 2011). Mutation p.E308D is physically close to p.A397K in GPR101 model. 
Overexpression of p.E308D and p.A397K GPR101 mutants in rat GH3 cells, but not wild type 
receptor lead to significant increase of cell proliferation and secretion of growth hormone 
(Trivellin et al. 2014). 
1.4.7. Somatostatin system 
Somatostatin (SST, also known as growth hormone–inhibiting hormone or growth hormone 
release–inhibiting hormone or somatotropin release–inhibiting factor somatotropin release–
inhibiting hormone) is a peptide hormone regulating endocrine system (Brazeau et al. 1973) 
and influencin neurotransmission (Epelbaum et al. 1994, Patel et al. 1995) and cell 
proliferation (Stewart and James 1999) via interaction of five somatostatin receptors which 
belong to G-protein coupled receptor family (Gahete et al. 2010). Somatostatin inhibits 
secretion of insulin, glucagon (Krantic 2000) and growth hormone (Brazeau et al. 1973, 
Panetta et al. 1994). There are five somatostatin receptors discovered in humans to date 
(SSTR1, SSTR2, SSTR3, SSTR4 and SSTR5 (Reisine and Bell 1995)) and also three natural 
antagonists are known cortystatin (Dalm et al. 2003, de Lecea et al. 1996) and two types of 
SST – somatostatin-14 and somatin-28 (Krantic 2000). 
Human genes for somatostatin receptors SSTR1 (located at chr14q13), SSTR2 (17q24), SSTR3 
(22q13.1), SSTR4 (20p11.2) un SSTR5 (16p13.3) do not contain introns (Yates et al. 2016, 
Krantic 2000). Functional receptors of all five types have been identified in central nervous 
system and endocrine glands. SSTR1 and SSTR2 are widely expressed throughout the body in 
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various tissues, while SSTR3, SSTR4 un SSTR5 expression is more localised. Meanwhile SSTR4 
mRNA have not been found in human pituitary (Dalm et al. 2003). 
SSTRs inhibit adenocyclasis (Gα 1-3) while selectively activating other transducers, such as 
phospholipase-Cβ as well as activating internally regulating K+ ion channel and current 
dependent Ca2+ ion channel (Patel 1999). 
The hypothesis stands that specific response to SSTR activation is dependent on co-
expression of SSTRs within the cell and interaction between functioning types of SSTR and 
their quantity (Cakir et al. 2010). SSTRs also can be constitutive activated (Ben-Shlomo et al. 
2013) and are regulated by endocytosis, internal trafficking and arrestin-mediated 
desensitization (Hofland and Lamberts 2003, Tulipano et al. 2004). 
1.4.8. Natural ligands of somatostatin receptors 
There are two naturally active forms of somatostatin (somatostatin-14 and somatin-28) and 
they have similar affinity to SSTR1-4 and in case of somatostatin-14 also to SSTR5, but 
somatostatin-28 has higher affinity to SSTR5 (Bruns et al. 2002). 
Cortystatin (CST) is cyclic neuropeptide consisting of eleven amino-acids which are similar to 
those of somatostatin (de Lecea et al. 1996). CST has affinity to all five SSTRs and is 
influencing neuronal activity and cell proliferation. CST is also involved in sleep pattern 
regulation and reduction of locomotor activity (Spier and de Lecea 2000) CST not only binds 
to SSTRs but also GH receptor (Deghenghi et al. 2001). CST and SST have similar effect on 
secretion of GH, PRL and insulin in patients with acromegaly or prolactinoma (Grottoli et al. 
2006). 
1.4.9. SSTR5 and pituitary adenomas 
Somatotatin receptor 5 (SSTR5) was discovered in 1993 (Sandford et al. 1996). SSTR5 is 
expressed in human brain and also in pituitary in adults and both pituitary and 
hypothalamus during human embryonic development (Patel 1999). There are two isoforms 
of mature SSTR5 consisting of five or four transmembrane domains and these isoforms are 
called SST5TDM5 and SST5TDM4, respectively. Both isoforms are functionally active but with 
different ligand binding properties. SST5TDM5 is preferably binding somatostatin (60%) and 
not more so CST (12%), meanwhile SST5TDM4 binds CST (43%) and only minute quantities of 
somatostatin (4%). Expression is differentiated between the two isoforms as well. SST5TDM5 
is expressed in tissues throughout the body and in a study was detected in seven out of 34 
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NFPA. SST5TDM4 isoform was rarely detected in normal tissues but found in 95% of PAs 
including somatotropinomas, corticotropinomas, NFPAs (Duran-Prado et al. 2009). A study in 
2000 discovered that SSTR5 together with dopamine D2 receptor (DRD2) is involved in 
formation of hetero-oligomers. This complex has elevated functional activity and leads to 
synergic reactions. Complexes with DRD2 could mean that SSTR5 in involved in psychiatric 
disorders and also suggest a role of DRD2 in pituitary (Rocheville et al. 2000). Clinical 
importance of SSTR5 is huge in case of GH secreting PAs. SSTR5 inhibits secretion of GH in 
somatotropinomas, leading to successful drug use in therapy of acromegaly and GH 
oversecretion (Saveanu et al. 2001). 
Literature mentions two polymorphisms that are clinically relevant: T461C and C1004T are 
associated with level of GH and IGF-1 in patients with acromegaly (Filopanti et al. 2005). 
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2. Materials and Methods 
2.1 LGDB DNA samples and phenotypic information 
All four studies were performed using genomic DNA samples acquired from the Latvian 
Genome Database (LGDB) biobank, which is funded by the Ministry of Health, Republic of 
Latvia. Participants are recruited and health status recorded by medical personal in 
hospitals and general practitioners located in Latvia. Individuals have to be at least 18 
years old. Diagnoses are based on approved criteria according to International 
Classiﬁcation of Diseases (ICD-10) codes. Anthropometric measurements (including 
weight and height) are acquired during a questionnaire-based interview. Ethnic, social, 
lifestyle and environmental information, as well as familial health status are self-reported 
and isn’t crosschecked. Recruitment was population based; a speciﬁc health condition 
was not required for involvement. The studies were carried out in accordance with the 
Declaration of Helsinki. The protocols for each individual study was approved by Central 
Medical Ethics Committee of Latvia. Written informed consent was obtained from all 
participants in all studies.  
DNA is extracted from the whole-blood leukocytes by phenol–chloroform method. 
DNA samples for the studies were provided by LGDB and aliquoted into 96 well PCR plates 
or PCR tubes by Tecan Freedom Evo robotic pipette (Tecan, Männedorf, Switzerland). 
Final DNA amount was 28ng per well.  
2.2 Study group description criteria 
We followed the Strengthening the Reporting of Genetic Association guidelines to 
describe selection of the study group and association analyses (Little et al. 2009).  
2.3 Study population 
2.3.1. Coronary artery disease study 
Study groups were selected from all 7936 participants recruited for the LGDB project from 
2003 to 2008. We initially excluded patients with cancer, renal diseases, variant angina 
(ICD-10 I20.1), cardiomyopathy (ICD-10 I42 and I43), and rare diseases (a complete list is 
available upon request). Participants with missing phenotypic data analyzed in this study 
were also excluded. After these exclusions were carried out, patients with CAD 
manifestations including angina (ICD-10: I20) and MI (ICD-10: I21 and I25.2) were selected 
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for the case group. The ﬁnal number of patients was 685. To avoid selection bias based on 
the hospital or a speciﬁc disease group, controls were randomly selected only from LGDB 
participants recruited by general practitioners. Patients with type-2 diabetes (ICD-10: E11) 
were not excluded from either case or control group. A total of 830 controls without 
cancer, CAD and its manifestations, renal or hepatic conditions, or thyroid disease were 
used in the present study. Information about smoking status, alcohol intake, and physical 
activity were self-reported. Individuals were designated ‘‘smokers’’ if they have smoked ≥ 
5 cigarettes a day for ≥ 12 months. Former smokers and current smokers were classiﬁed 
according to these criteria. Physical activity was classiﬁed according to self-reporting of 
previous physical activity. The non-consumers group comprised individuals who had the 
following behaviors: not consuming alcohol; consuming alcohol less than once a week; or 
drinking less than 1.5 units of alcohol per week. The remainder of the group was 
designated ‘‘alcohol consumers.’’ The study was approved by the Central Medical Ethics 
Committee of Latvia (Resolution A-5, March 22, 2007). 
2.3.2. GLO1 activity study 
In total, 326 participants were recruited for case-control study: 101 patients with T1D, 
100 patients with type 2 diabetes T2D, and 125 non-diabetic individuals. All control 
participants and patients were of European descent. Exclusion criteria were chronic renal 
failure (glomerular ﬁltration rate less than 60 ml/min), chronic liver disease, an active 
inﬂammatory disorder (white blood cell count > 8.5 × 103/mm3), an erythrocyte 
sedimentation rate > 20 mm/h, or high-sensitivity C-reactive protein > 15 mg/l (because 
high levels may indicate a latent chronic inﬂammatory condition), anemia, current 
evidence or a history of malignancy in the last 5 years, a history of drug or alcohol abuse, 
and causes of neuropathy other than diabetes. The study was approved by the Central 
Medical Ethics Committee of Latvia (Resolution A-9, May 29, 2006). 
2.3.3. Pituitary Adenoma study 2009 
The acromegaly patients (total N=48) used in this study were enrolled to the LGDB from 
2004 and 2008 from two main hospitals, Pauls Stradins Clinical University Hospital (N=41) 
and Riga Eastern Clinical University Hospital (N=7) and they represented approximately 
80% of all the acromegaly patients registered in Latvia as of October 2008 (diagnosed 
with acromegaly from 1985 to 2007). Additional data were collected based on hospital 
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records and interviews for all the patients selected for this study (ICD-10 code E22.0). 45 
patients received the somatostatin analogs octreotide (Sandostatin®LAR) at dose 10-30 
mg in every 28 days and lanreotide (Somatuline®Autogel®) at dose 60-90 mg every 28 
days. Tumor size was measured as the maximum diameter obtained from magnetic 
resonance imaging data and tumors were classified accordingly as microadenomas 
(<10mm) or macroadenomas (>=10mm). The effect of somatostatin analogs on tumor 
proliferation and insulin-like growth factor 1 (IGF-I) level normalization was estimated by 
comparing the tumor sizes and serum IGF-I (µk/ml) measurements during the course of 
therapy. In order to estimate the dynamics of adenoma size, the data from last follow-up 
was compared with the first available measurement with at least 12-month period in 
between. We excluded all cases where the therapy was interrupted or adenoma 
resections were performed during this period of time. Two groups were defined: 
“reduced” with observable tumor shrinkage (N=11) and “unchanged” with no observable 
tumor shrinkage (N=22) together with the cases that showed prolonged expansion (N=2). 
Only a limited number of cases had IGF-I measurements available before the therapy. For 
the IGF-I response, only the data at least 6 months after the start of the SA therapy were 
considered for analysis and only if the therapy was not interrupted. In those cases, where 
several IGF-I measurements were available, the mean IFG-I was calculated, excluding the 
outliers when that was possible. Non-responsiveness was defined as the mean IFG-I value 
above the upper limit of the normal value at the corresponding age. Due to the lack of 
uniformity in the GH measurements, we did not include the GH levels in this analysis.  
Two independent control samples were used in this study in order to minimize the risk of 
false association. 
Control I was 96 samples randomly chosen for sequencing from total of 2203 LGDB 
participants recruited from 2003 to 2005 excluding patients with metabolic and endocrine 
diseases. Control II group was sex and age matched to cases and consisted of 475 LGDB 
participants. This group was selected from all of the 7935 LGDB participants recruited 
from 2003 to 2008 applying the following selection criteria. First we excluded subjects 
having any chronic disease including metabolic, endocrine, coronary heart, cancer and 
renal conditions. Similarly, we excluded all participants with missing the relevant 
phenotypic data. After this selection 1225 healthy adults were considered for further use. 
Matching by age was performed in ten-year age groups randomly choosing ten sex 
matched controls for each acromegaly patient from the corresponding age group. Five 
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samples were omitted due to the practical reasons (96 plate format). Under these criteria 
63 participants from the Control I were also included in the Control II group. Study 
protocol was approved by Central Medical Ethics Committee of Latvia (Protocols No A-33, 
2005 and A-3, 2008).  
2.3.4. Pituitary adenoma study 2016 
The case group (165 participants) was enrolled for this study from the LGDB between 
2004 and November 2011. Two university hospitals involved in the treatment of PA in 
Latvia participated in the enrollment of study cases. One hundred and fifty-eight patients 
were recruited from Pauls Stradins Clinical University Hospital and seven patients were 
from Riga Eastern Clinical University Hospital. Hormonal profiles (typically levels of GH, 
prolactin, IGF-I, ACTH, and others, depending on the presence of clinical indications) from 
the blood were determined at an independent commercial laboratory (E. Gulbis 
Laboratory, Riga, Latvia) and used for the diagnosis. Prolactin was detected by 
electrochemical luminescence with Cobas 6000 (Roche, Basel, Switzerland), while GH, 
IGF-I, and ACTH levels were measured with Imulite 2000 (Siemens AG, Berlin, Germany). 
In cases with elevated levels of these hormones, magnetic resonance imaging (MRI) was 
performed. The presence of a pituitary tumor was determined using high-definition MRI 
data from a 1 mm slice series of the pituitary gland without contrasting agent with a 
Siemens Magneton 1.5T (Siemens AG, Berlin, Germany). During the first visit to the 
endocrinologist, phenotypic features (primary diabetes, primary hypertension, heart 
dysfunction, carpal bone syndrome, sleep apnea, macrognathia, and morphology of the 
nose and frontal bone) were also considered in the diagnosis, and further blood serum 
hormone testing was performed. Data used in this study include sex, age, age at tumor 
diagnosis, PA size, presence of extrasellar growth, and hormone-secreting type, 
treatment type, drug prescription information, and the occurrence of other tumors. PA 
was designated as a “macroadenoma” if its diameter according to the MRI data was 
larger than 10 mm. It must be noted that age at diagnosis does not correspond to the age 
of tumor incidence or age when clinical symptoms attributed to PA occurred. Phenotypic 
data were collected based on hospital records and interviews for all the patients selected 
for the study. Samples were excluded from the study due to missing phenotype data (age 
or sex; N=9), misdiagnosed as having PA in the primary examination (N=5), inadequate 
DNA sample quality (N=2), or re-diagnosis as a pituitary carcinoma (N=1). Due to the low 
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number of cases, we also excluded patients with Cushing’s disease (N 4). This left 144 
cases eligible for genotyping. Age- and sex-matched controls were selected from LGDB 
participants without endocrine or metabolic diseases or other chronic disease. Matching 
of samples was performed by dividing the case sample into groups based on sex, then 
further dividing subjects into age bins by decade of age. The sample of suitable controls 
(N=738) was divided in a similar manner. Controls were picked randomly from each 
subgroup according to a number based on each respective case group. Samples with 
phenotypic information missing (e.g., sex, age, or BMI) were excluded from random 
matching. It should be noted that sex and age matching was performed before 
genotyping, and thus, it was influenced by exclusion of some samples as a result of 
genotyping quality check. However, the medians of age and interquartile range remained 
similar for all respective case–control groups, and in case of linear and logistic regression, 
sex was used as a covariate controlling for this issue. A total of 365 controls and one inter-
plate positive control were used in this study. The case-to-control ratio was 1:2.5. The 
study protocol was approved by the Central Medical Ethics Committee of Latvia (protocol 
no. 01.29.1/28, December 14 2011). 
2.4 Target selection of genetic variants 
2.4.1. Coronary artery disease study 
The aim of the study was to evaluate the role of non- synonymous SNPs in ADORA3 with 
respect to susceptibility to CHD. Four nonsynonymous SNPs have been detected in 
ADORA3 and are listed in the SNP database of the National Center for Biotechnology 
Information (dbSNP, build 131): rs55653224, rs35986308, rs35511654, and rs2800889. 
We considered only SNPs that were present in a population of European descent with a 
minor allele frequency (MAF) of ≥0.01. Only rs35511654 corresponded to the 
aforementioned criteria and was therefore selected for analyses. 
2.4.2. Glyoxalase 1 study 
We selected three SNPs (rs2736654, rs1130534, rs1049346) in the GLO1 gene using the 
following selection criteria: SNPs located inside the coding region or in close proximity 
(within 0.1 kb) of GLO1, and SNPs with MAF ≥0.1 in the European population, based on 
information in the NCBI SNP database (Yates et al. 2016). 
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2.4.3. Pituitary adenoma study 2009 
Somatostatin acting through the somatostatin receptors is regulating GH secretion and 
regulation of tumor proliferation. SSTR2 and SSTR5 are found in high levels in 
somatotropinomas of pituitary. Also somatostatin analogues octreotide and lanreotide 
that have the highest affinity to SSTR2 and SSTR5 are used to repress GH synthesis and 
tumor proliferation in acromegaly patients. Direct sequencing of the SSTR5 gene were 
chosen to gain comprehensive view of SSTR5 mutations in patients with acromegaly. 
2.4.4. Pituitary adenoma study 2016 
Seven candidate genes were selected based on an extensive literature search about 
known and probable PA genetics in February 2011. The genes chosen were AIP, MEN1, 
GNAS, SSTR2, SSTR5, PRKAR1A, and DRD2. Tag SNPs were selected within these genes 
and in the upstream and downstream regions in strong linkage disequilibrium (r2 > 0.8) 
with markers within each gene using Haploview v4.2 software (Barrett et al. 2005) and 
HapMap release #28 (NCBI build 36, dbSNP b126, CEU analysis panel) (International 
HapMap 2003) project information available in February 2011. Nonsynonymous SNPs in 
these genes were also included, and the remaining two slots in the 96-SNP assay were 
filled with the most informative tag SNPs from PRKAR1A. Detailed information about the 
regions chosen and linkage disequilibrium plots are available at supplementary 1. The SNP 
list generated by Haploview v.4.2 (Broad Institute, Cambridge, USA) was analyzed by the 
Illumina Assay Design Tool (Illumina, San Diego, USA). SNPs with low predicted 
genotyping success rates were removed and each gene was reanalyzed in Haploview 
using the “force exclude” option for the marked polymorphisms. The designated 
genotyping success rate of 0.5 was deemed acceptable in cases where no other SNP was 
present to capture the marker or important nonsynonymous variant selected. Otherwise, 
a “Designability Rank = 1” was required. The final number of SNPs corresponded to the 
requirements of the Custom VeraCode GoldenGate Genotyping platform, offering 
discrimination of 96 SNPs in a single well of a 96-well microplate as one of the standard 
options. A full list of SNPs is located at supplementary 2.  
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2.5 DNA analysis 
2.5.1. PCR, SSTR5 amplification 
The SSTR5 gene containing genomic DNA region including 5’ and entire coding region 
(from –2239 to +1294 respective to start codon) were amplified in six PCR reactions. PCR 
primers for DNA amplification were designed using Primer3 software (primer sequences 
can be found in Supplementary 3A). Following PCR reaction setup was used: 1mM BD 
buffer, 2,5mM MgCl2, 0,5 units Hot FirePolymerase, 0,2mM dNTP mix (SolisBioDyne, 
Tartu, Estonia), 0,3mM primers and 28ng template DNA. PCR temperatures were 95°C – 
5min, 40 cycles – 95°C – 30s, 55°C – 30s, 72°C – 1min, and 5min at 72°C for final extension 
and the PCRs were carried out on Veriti96Therma Cycler (Applied Biosystems, Foster City, 
USA). 
2.5.2. PCR, MEN1 validation 
Polymerase chain reaction primers were 5′- CAGAAGGTGCGCATAGTGAG-3′ and 5′- 
GGTCCGAAGTCCCCAGTAGT-3′. Following PCR reaction setup was used: 1mM BD buffer, 
2,5mM MgCl2, 0,5 units Hot FirePolymerase, 0,2mM dNTP mix (SolisBioDyne, Tartu, 
Estonia), 0,3mM primers and 28ng template DNA. PCR temperatures were 95°C – 5min, 
40 cycles – 95°C – 30s, 60°C – 30s, 72°C – 30s, and 7min at 72°C for final extension and 
the PCRs were carried out on Veriti96Therma Cycler (Applied Biosystems, Foster City, 
USA). 
2.5.3. Agarose gel electrophoresis 
The presence of PCR products were confirmed by 0,8% agarose gel electrophoresis. 
2.5.4. Purification of PCR products  
Dephosphorylation of remaining dNTPs was done with shrimp alkaline phosphatase 
(Fermentas, Vilnius, Lithuania/ Thermo Fisher Scientific, Waltham, USA) according to 
manufacturer’s protocol. Restriction endonuclease ExoI (Fermentas, Vilnius, Lithuania/ 
Thermo Fisher Scientific, Waltham, USA) was used to remove leftover primers. This 
cleanup ensures the best results for Sanger sequencing. 
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2.5.5. Sanger sequencing 
SSTR5 gene amplification products had both strands directly sequenced using a set of 14 
primers that were designed on Primer3 Software v.2.2.0 (Universität Heidelberg, 
Heidelberg, Germany) (Untergasser et al. 2012) (Supplementary 3B). 
Sanger sequencing was performed to confirm MEN1 rs2959656 heterozygous state in 
seven carriers discovered by Illumina BeadXpress genotyping. Sequencing primers were 
5′- CAGAAGGTGCGCATAGTGAG -3′ and 5′- GGTCCGAAGTCCCCAGTAGT -3′. 
Following sequencing reaction setup were used: 1µl BigDye, 2µl 5x BigDye sequencing 
buffer, 0,5mM corresponding primer, 150-250ng of template DNA (from the previously 
described PCR reactions) and 5.5µl distilled H2O. Reaction conditions were set: 96°C – 
1min, 25 cycles - 96°C – 10s, 50°C – 5s, and 60°C – 4min. PCR was carried out on Veriti96 
Thermal Cycler (Applied Biosystems, Foster City, USA).  
The products were purified using Sephadex G50 (Sigma-Aldrich, St. Louis, USA) and 
sequenced with ABI Prism 3100 (AME Bioscience, Torod, Norway) capillary 
electrophoresis sequencer. All chromatograms were manually inspected using Contig 
Express software of Vector NTI Advance 9.0 package (InforMax Inc, North Bethesda, USA) 
or in case of MEN1 sequencing – FinchTV v.1.4.0 (Perkin Elmer, Waltham, USA). Presence 
of polymorphisms was also confirmed by opposite strand analysis.  
2.5.6. MALDI-TOF genotyping 
Genotyping were carried out using mini-sequencing and subsequent MALDI-TOF mass 
spectrometry analysis. Special primers for mini-sequencing were designed using the 
program CalcDalton (Kirsten et al. 2006)(University of Leipzig, Leipzig, Germany). These 
primers (Supplementary 4) contained biotin cap on 5’ end and photosensitive linker 
cleavage site. Mini-sequencing reaction setup: 0,5mM 10xC buffer, 1,25mM MgCl2, 1 unit 
TermiPolDNAPol (Solis BioDyne, Tartu, Estonia), 0,2mM ddNTPs (Fermentas, Vilnius, 
Lithuania), 1mM primers mentioned above and 5μl of PCR product.  
Mini-sequencing conditions were 95°C – 2min, 99 cycles – 95°C – 10s, 55°C – 10s, 72°C – 
10s, and finishing 72°C – 5min. After mini-sequencing products were precipitated on 
streptavidin coated 384-well plates (Biotez, Berlin, Germany) and subjected for ultraviolet 
exposure for 15 min. After purification 1μl of DNA mini-sequencing sample where diluted 
in 1μl of 3 –hydroxypicolinic acid matrix (70mM and 40mM di-ammonium hydrogen 
citrate), spotted on MTP AnchorChip 400/384TF (Bruker Daltonics, Billerica, USA) and air 
56 
 
dried. MALDI-TOF MS analyses were carried out on MALDI-TOF mass spectrometer 
(Bruker Daltonics, Billerica, USA) using maximum 40 nitrogen laser shots with frequency 
16,7 Hz on each sample spot. Oligo calibration standard LMW (Bruker Daltonics, Billerica, 
USA) were used for mass calibration in interval 1000 - 4000 Da. We used the following 
mass intervals for the genotyping; rs34037914 intervals 3500 – 4500 Da, for rs169068 – 
3000 – 4000 Da, for rs642249 – 4000 – 5000 Da. 
Results were analyzed using Genotools SNP Manager software v2.2 (Bruker Daltonics, 
Billerica, USA) and manually verified.  
2.5.7. TaqMan genotyping  
DNA samples were aliquoted from storage tubes into 96- well PCR plates using a Tecan 
Freedom Evo system (Tecan, Mannedorf, Switzerland) with disposable ﬁlter tips. DNA 
concentration was normalized to 7 ng/ml. Genotyping was carried out using an Applied 
Biosystems TaqMan SNP Genotyping Assay with a modiﬁed protocol using 4.75 ml 
TaqMan Genotyping Mix (Applied Biosystems, Foster City, USA), 0.25 ml SNP genotyping 
assay ID C_25626674_20 (Applied Biosystems, Foster City, USA) and 5 ml Millipore H2O 
(Millipore, Bedford, USA) on a 7500 Real-Time PCR system (Applied Biosystems). 
AutoCaller 1.1 (Applied Biosystems, Foster City, USA) software was used to 
simultaneously assign genotype calls for all samples. Samples with unsuccessful 
genotyping were removed. 
2.5.8. Illumina BeadXpress genotyping 
All 96 SNPs were genotyped using the Illumina BeadXpress system (Illumina, San Diego, 
USA) with Illumina GoldenGate genotyping assay (Illumina, San Diego, USA) (Lin et al. 
2009). Genotyping was carried out according to the manufacturer’s instructions. In order 
to ensure quality control and a high intra-subject concordance rate, 46 or 9.3% DNA 
samples were randomly chosen and distributed to other plates for repeated genotyping. 
All quality control steps in the manufacturer’s instructions were implemented. One 
sample was used as a positive control across all plates. There was >99.98% observed 
genotype concordance; with one mismatched allele call in 46 repeat pairs (one out of 
5796 alleles obtained), excluding uncalled alleles. Additionally, one mismatched allele call 
was observed among seven inter-plate controls; therefore, no assay plates were removed 
from the study due to excessive genotype mismatch. Primary genotyping data analysis 
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was performed by Illumina GenomeStudio V2010.3 Genotyping module V1.8.4. software 
(Illumina, San Diego, USA). The Gene Call threshold was set to 0.25. The cluster images of 
the signal intensity were manually reviewed.  
2.5.9. Glo1 enzyme assay 
Glo1 activity was determined in whole blood samples on the day of the blood collection, 
according to a method described in (Skapare et al. 2011). 
2.5.10. Statistical analysis 
Statistical analyses were undertaken with the PLINK 1.06 and v1.07 software (Purcell et al. 
2007). Deviation from the Hardy–Weinberg equilibrium was assessed by the exact test 
described by (Wigginton et al. 2005) which is more accurate for rare genotypes. The 
Cochran–Armitage trend test was used for unadjusted association analysis. Logistic 
regression assuming an additive, dominant, or recessive mode of inheritance was 
employed to adjust the analysis for other non-genetic factors. Sex, age, body mass index 
(BMI), diabetes, smoking, alcohol consumption, and physical activity were included in the 
logistic regression models as covariates. Linear regression was used to determine 
relationships between genotypes and quantitative variables with and without covariates 
(sex, age, BMI, smoking, alcohol consumption, history of statin and ACE inhibitor/ARB 
therapies). 
Haplotype association was performed as implemented in PLINK. 
Normal distribution was determined using the Kolmogorov–Smirnov test. 
To minimize the false-positive results, given the relatively small sample size, we carried 
out a permutation test with a ‘label swapping’ method using identical parameters; 
100,000 permutations were used including the correction for multiple testing (EMP2 
value).  
The Chi-square test and Student’s t-test were used to compare characteristics between 
case and control groups. Mann–Whitney rank sum test was used to compare quantitative 
variables that are not normally distributed. 
P values <0.05 after adjustment for Bonferroni multiple testing correction were 
considered to indicate statistical signiﬁcance. P values lower than 0.05 before multiple 
testing correction were deemed noteworthy and their biological relevance was examined 
closer. 
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In the 2009 study of PA the IGF-I data were transformed as a normalized percentage of 
upper limit of normal (ULN) of appropriate age according to formula (CIGF-I – ULNIGF-
I)/ULNIGF-I x 100). Normalized IGF and all other continuous variable displayed normal 
distribution and were further used in linear regression analysis. Two sided Fisher exact 
test was used to test the allelic distribution in case of categorical clinical variables, except 
the analysis of number of adenoma resections where Pearson Chi-Square was calculated 
from 3x3 table. 
Statistical power was calculated using Quanto software v1.2.4 (Natara Software, 
Naperville, USA) (Gauderman 2002) for SNP with frequencies of 1, 5, 10, and 50% using 
the assumptions of gene-only hypothesis, log-additive inheritance, and a population risk 
from 0.001 to 0.01 by 0.05 in a two-tailed test using our sample. 
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3. Results 
3.1 A Nonsynonymous Variant I248L of the Adenosine A3 Receptor Is Associated 
with Coronary Heart Disease in a Latvian Population 
  
60 
 
61 
 
  
62 
 
  
63 
 
  
64 
 
  
65 
 
3.2 Identiﬁcation of glyoxalase 1 polymorphisms associated with enzyme activity 
Author of the thesis is the joint first author in “Identiﬁcation of glyoxalase 1 polymorphisms 
associated with enzyme activity”.  
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3.3 Polymorphisms in MEN1 and DRD2 genes are associated with the occurrence 
and characteristics of pituitary adenomas 
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3.4 Identification of Somatostatin Receptor Type 5 (SSTR5) gene polymorphisms 
associated with acromegaly 
The author of the thesis is fourth listed author in the 2009 publication “Identification of 
Somatostatin Receptor Type 5 (SSTR5) gene polymorphisms associated with acromegaly”, 
where he performed independent checking of results and supporting data tables, edition of 
the manuscript, implementing changes and clarifications as requested by the referees. 
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4. Discussion 
Multifactorial or non-communicable diseases, which are contributing to a severe increase in 
human morbidity and mortality, are on the rise throughout the world and they are 
burdensome to national healthcare systems. 
Uncovering the genetics of multifactorial diseases may help to understand their molecular 
mechanisms which can lead to a targeted search for therapies, precision medicine 
approaches tailored to the individual, and more effective use of (always) limited healthcare 
funding. 
Three broad classes of multifactorial diseases, which include cardiovascular diseases 
(especially CAD), diabetes and tumors; most of which are malignant, are the main cause of 
disability adjusted life years lost worldwide (Murray et al. 2012). 
These conditions are being observed more frequently due to population aging trends, 
human population expansion, a greater awareness of these diseases, improved diagnostic 
capacity, and their share in total disease burden is increasing (Das and Samarasekera 2012, 
Murray et al. 2012). 
CAD, diabetes and pituitary adenomas are connected at a physiological level since hormonal 
imbalances caused by pituitary adenoma can lead to diabetes insipidus. An increase in 
glucose levels due to diabetes is a stress factor for endothelium cells and is therefore 
associated with atherosclerosis; an underlying process in CAD. PA includes various 
cardiovascular conditions. These conditions seem to share the same genetic architecture 
from a causal perspective and are a heterogeneous group of diseases with shared symptoms 
and endpoints from a molecular perspective. This makes these disorders prime targets for 
theranostics (Choi et al. 2015, Patel and Janjic 2015). CAD, diabetes and pituitary adenomas 
are each associated with multiple genetic variations, intermediate phenotypes, and 
complications. Novel genetic markers are still being found after decades of scientific 
research (Nikpay et al. 2015). Missing heritability and disease mechanisms from established 
genetic risk factors and associated phenotypes is still not understood in detail. The vast 
majority of studies on multifactorial diseases have been conducted in Western European or 
American populations. This has led to many important discoveries but has also introduced 
population biases. Much information that could consequently have been acquired due to the 
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scale by which research efforts were launched and financial resources that were invested, 
has been missed (Kessler et al. 2016). 
4.1 Adenosine receptor gene variants as possible minor modulators of CAD 
Adenosine and its four receptors (A1, A2A, A2B and A3) play a role in cardio protection in 
ischemia cases. This is achieved by limiting the damage caused by a decrease in, or complete 
lack of, oxygen due to obstructed blood flow in the coronary arteries of the heart. A large 
meta-analysis of GWAS studies for the imputation of genetic variants was based on 
information obtained from the 1000 Genomes Project. The meta-analysis identified variation 
near the A2A receptor where the common allele G is significantly associated with an 
increased risk of CAD (OR=1.20, CI 0.95=1.13-1.27, P=1.60x10-10) (Nikpay et al. 2015).  
The lead SNP rs180803 (Chr22q11.23 POM121L9P – ADORA2A) is located in the non-coding 
RNA POM121 transmembrane nucleoporin-like 9 pseudogene (POM121L9P) locus (Yates et 
al. 2016).  
A genome-wide significant association (P<5x10-8) was observed for 21 variants in a 1.2Mb 
region. The majority of these variants are located in introns of A2A and SPECC1L genes. They 
are also in high LD (R2>0.6) with the rs180803 lead variant (Nikpay et al. 2015). This adds to 
the evidence that genetic variations in the adenosine system are involved with cardio 
protection. Our study published in 2011 was focused on the adenosine A3 receptor located 
on chromosome 1p13.2, and its associated variant (dbSNP ID rs35511654). Modest 
protective action of the minor allele C was observed (OR=0.71, CI 0.95=0.53–0.96) (or 
increased OR for the common allele to 1,41). The variation causes a missense mutation 
which changes the amino acid of the A3 receptor in 248th position from isoleucine to leucine. 
Chemically, these amino acids are closely related; the only difference is the branching point 
of the side chain. Nevertheless, in the case of the A3 receptor and the rs35511654 variant, 
the position of the variant could crucially influence the binding capacity of the agonist. 
Functional studies have reported that nearby amino acid positions are important for the 
recognition of agonists and antagonists (p.250 N, two amino acid residues away and p.247 S, 
one amino acid residue away). Moreover, the W243 amino acid, which is five positions away 
from altered position by rs35511654, is implicated in signal transduction while the E239 
amino acid (nine positions away from p.248 I) is associated with receptor activation (Gao et 
al. 2002). The various three-dimensional space requirements of different side chains, as 
coded by rs35511654, could lead to modified spatial distances. This subsequently could lead 
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to either enhanced recognition of agonists, signal transduction or receptor activation, or 
decreased recognition of antagonists. This would be in line with the protective nature of the 
minor allele, as shown in our study. Usually, depending on the cell type and tissue in which it 
is located, one component in human cells has various roles. This could be the same in the 
case of A3R in that it could be utilized in protecting the heart and its blood vessels. 
Alternatively, it could act as a protector from reperfusion injury in a way that is different in 
immune cells since A3R inhibits the release of TNF-alpha from monocytes; the main drivers 
of plaque formation in the coronary arteries (Zhang et al. 2005). Due to the different 
regulation in different cell types, the impact of the rs35511654 polymorphism could vary 
depending on the tissue it is located in.  
Nevertheless, our observation has not been confirmed in candidate gene studies or GWAS 
analyses in any other population. A prominent hotspot for CAD-associated variants was 
found to be 2.22Mb away in a GWAS study. The rs646776, rs599839, rs12740374, and 
rs629301 polymorphisms are located in a noncoding DNA region between the CELSR2 and 
PSRC1 genes (Musunuru et al. 2010). It was found that this locus is associated with increased 
LDL cholesterol levels as well as an increased risk of MI and that the risk allele is common 
one (Samani et al. 2007). According to Musunuru et al. the mechanism of the lead 
rs12740374 SNP is an increase in PSRC1 and SORT1 expression in the liver and a resulting 
increase in very small dense LDL particle levels in the blood (Musunuru et al. 2010). 
According to literature, these very small dense LDL particles are more important in 
promoting atherogenesis than LDL in larger aggregations (Berneis and Krauss 2002). The 
most interesting finding from our study is that the common allele predisposes individuals to 
an increased risk of developing CAD. It is possible that the rs35511654 variant from our 
study serves as a weak proxy to the PSRC1/SORT1 risk-associated variants. This observation 
could become more succinct through the genotyping of the 1p13.2 locus to establish if there 
is linkage disequilibrium between the variants in the Latvian population. The second 
interesting point is that an additional member of the adenosine receptors, A2A, is situated at 
a locus where the common allele increases CAD risk (Nikpay et al. 2015). These facts allow us 
to formulate the hypothesis that evolution is selecting for cardio-protecting variants and 
that their frequency is on the rise in the general population. 
The majority of large scale CAD studies have been performed using populations of Western 
Europe descent (Table 2, Table 3). This choice was logical because of the advancement in 
science and economic situations in the countries where the studies were conducted. Despite 
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this, these studies have probably only captured a small part of the genetic variation 
contributing towards human CAD. Indeed, while trying to narrow down the variation 
responsible for the increased CAD risk, a study has used African American samples in order 
to single out the most likely candidate (Musunuru et al. 2010). The same approach is 
possible between populations from Latvia and other Western European nations where 
unique environmental settings, distinct histories and relative isolation has led to the 
emergence of different genetic patterns within individual populations. The genetic patterns 
may have arisen so as to cope with the various socio-economic factors, pollution levels and 
lifestyle choices. The effect and contribution of each factor involved, whether genetic, 
lifestyle, or environmental, could therefore lead towards changes in CAD risk. 
4.2 GLO1 variants are strong determinants of glyoxalase activity 
GLO1 is the frontline cellular defense against damage induced by AGEs. This protection is 
especially important in environments with elevated blood sugar levels such as that observed 
with diabetes and cells which use glucose as the main source of energy, such as neurons 
(Howarth et al. 2012). It has been shown that human neurons consume disproportionately 
large amounts of glucose relative to their mass (Mergenthaler et al. 2013). It is thus 
unsurprising that the main diabetes complications start with neuronal dysfunction such as 
neuropathic pain and diabetic retinopathy (Chilelli et al. 2013). The former condition affects 
the peripheral nerves in diabetic patients over time leading to pain, tingling, or numbness in 
the hands, arms, feet, and legs. The latter condition is the foremost cause of vision loss in 
diabetic individuals of all ages, and top cause of vision impairment and blindness among 
adults in the working-age group (The 2015). Yet, not all diabetes patients have these 
complications and those that do may manifest symptoms at different time points following 
the onset of diabetes. Disease progression rates may also vary between patients. A number 
of studies have been performed trying to link the genetics of GLO1 with diabetes 
complications since GLO1 is the main detoxification enzyme in the human body and diabetes 
complications are thought to be caused by AGEs. Given the amount of disorders where 
enzyme disruption is the leading cause of pathology, this is not surprising (National 
Organization for Rare Disorders 2006, The Genetic and Rare Diseases Information Center 
2002). Results can however be inconsistent. For example the same, single study found that 
the rs2736654 A allele was not associated with nephropathy or retinopathy in an East Asian 
population, while rs1049346 was associated with both complications in patients with type 2 
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diabetes in the same population (Wu et al. 2011). Similarly, no associations were found 
between nine tag-SNPs in the GLO1 gene and vascular complications in diabetes patients of 
European ancestry (Engelen et al. 2009). Results of our study did not show a direct 
association between the studied GLO1 polymorphisms and diabetic neuropathy, 
nephropathy and retinopathy in either type 1 or type 2 diabetes patients. This leads to the 
obvious conclusion that the glyoxalase system is not the only factor influencing the 
development of diabetic complications, but add to the risks associated with this 
multifactorial disorder. Interestingly, the only SNP in our study that was not significantly 
associated with changes in enzymatic activity was found to change the qualitative 
composition of the enzyme. Although haplotype analysis data allows to hypothesize that it 
still modifies the effect of the both SNPs significantly associated to GLO1 activity. Several 
studies have shown how intronic SNPs and SNPs present near genes can influence properties 
of the associated gene, and often properties of distant genes (Cooper 2010). Actually, 
instead of the more easily understandable changes in amino acid sequence of a 
protein/enzyme, SNPs found outside of gene coding regions are most commonly associated 
with a wide range of multifactorial disorders (Muller et al. 2016). Alternative splicing is a 
common mechanism by which noncoding SNPs could influence the amount or type of gene 
product made. In the case of GLO1, only one type of enzyme protein had been discovered in 
humans by 2017. Another transcript, which encompasses exons 4-6 and also includes 
rs1130534 (minor T allele associated with decreased GLO1 activity) and rs2736654 (missense 
SNP), constitutes a 7.27kb GLO1 fragment. Another possibility is that one or both minor 
alleles of these SNPs disrupt the expression of GLO1 leading to lower concentrations and 
activity of the enzyme.  
Overall, it is likely that a lower activity of GLO1 in carriers of each of the minor alleles of the 
associated SNPs contributes towards the development of diabetic complications, but only in 
interaction with other environmental and genetic factors that modify the severity, timing 
and type of developing complication. Weaker enzyme action, together with other 
unbalanced elements, is likely to lead to more pronounced or earlier complications. To fully 
understand the involvement of GLO1 and its interactions with the causes and complications 
of diabetes, considerable additional research and innovation is required to elucidate the 
molecular basis and modifying factors of diabetes. 
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Also it would be interesting to, in a prospective study, investigate if the alleles that 
contribute to the development of diabetic complications are significant determinants in the 
cause of death of T2D patients. 
4.3 SSTR5, MEN1 and DRD2 contribute to pituitary adenoma development and 
associated clinical characteristics 
Pituitary adenomas are benign tumors of the pituitary gland. The genetic cause of PA is 
heterogeneous and similar to that observed in most of the recognized multifactorial 
diseases. Classical subdivision of PA is based on the type of hormone/s secreted by the 
tumor. Functional PAs include prolactinomas, somatotropinomas, gonadotropinomas, TSH-
secreting PAs, ACTH-secreting PAs, and PAs that secrete at least two hormones (mixed PAs). 
The remaining PAs are categorized as non-functional. This classification makes sense from a 
clinical point of view since hormonal imbalances lead to different clinical symptoms which 
require different treatment strategies. It becomes clear during the course of treatment that 
these broader categories encompass different types of PAs as the response to treatments 
and progression of neoplasms are often patient-specific. Also, when treating NFPAs, some 
patients occasionally respond to the treatment that is supposed to work on a functional PA 
type. This has led to the proposal that a molecular classification system of PA could help to 
improve the treatment and subsequently, the outcome of the disease. Under closer 
investigating of NFPA tissue samples through immunohistochemistry, some neoplasms 
showed that although hormones are produced, they are retained within cells and not 
secreted. In Latvia, patients are not always examined for the presence of gonadotropins due 
to limited funding for diagnostic tests. Therefore, these patients are usually classified 
alongside the NFPA group.  
Monoclonality of PA was described during the 1990’s; a fact that went unchecked with 
despite the availability of more modern genetic analysis methods (Jacoby et al. 1990). 
While some genes causative of PA have been known for years (Pellegata et al. 2006, 
Stratakis and Ball 2000), genetic causes for different types of PA have only recently been 
discovered and reported (Beckers et al. 2015, Ma et al. 2015, Perez-Rivas et al. 2015, 
Reincke et al. 2015, Trivellin et al. 2014). 
Studies performed by us have provided insight into several interesting genetic aspects of PA. 
The rationale behind the SSTR5 studies was that SSTR5 is expressed in somatotropinomas 
and, together with SSTR2, controls GH secretion and body growth (Panetta et al. 1994). At 
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the time the research was conducted, no studies had performed a comprehensive genetic 
investigation of SSTR5 in cases of somatotropinomas. 
In this first study, two variations in SSTR5 (rs34037914 and rs642249) were associated with 
acromegaly-causing somatotropinomas.  
The synonymous rs34037914 polymorphism was also associated with several independent 
characteristics that, when taken together, could clinically be described as more severe 
acromegaly. This was based on the finding that patients had a lower response to SA analogs, 
higher IGF-1 levels, and were more likely to have tumor surgery and recurrent PA surgery.  
In the second study, six candidate genes (SSTR2, DRD2, AIP, MEN1, GNAS, PRKAR1A) were 
added in addition to the previously investigated SSTR5 gene in studying the three most 
common types of PA (prolactinomas, NFPA and somatotropinomas).  
When researching the genetic causes of PA, we favored an approach similar to that used in 
studies focused on other multifactorial diseases. This approach is justifiable since PA is 
common in the general population (Ezzat et al. 2004). However, only a small percentage of 
PA cases become clinically significant during the lifetime of the patients. This leads to the 
main problem associated with PA genetic studies which is the relative rarity of the clinically 
significant condition. Also, the availability of verified PA-free controls is a problem, as quick, 
cheap and patient-friendly tests do not exist. The best candidates for control samples would 
probably be patients with brain scans performed for other reasons (like stroke etc.). 
The main discovery in the second study was the presence of rare, non-synonymous variation 
in the well-known PA gene – MEN1. The rs2959656 variant was found in seven PA cases and 
in only one control sample. While there was no predominant PA type associated with 
rs2959656, five of the carriers had clinically significant microadenomas. This suggests that PA 
is associated with this variant which either leads to an earlier presentation of PA symptoms 
or slow growing tumors. Although it is a missense variant, it is unlikely that rs2959656 alone 
is the cause of PA. It is a rare variant in populations of European descent, while it is fairly 
common in East Asian, American and African populations where it can reach a MAF of up to 
0.40. We therefore propose that this variant is a marker for PA only in European 
populations, and further suggest that rs2959656 is either in LD with a causal variant, or 
works in synergy with additional variants in MEN1 or genes in other locations. Alternatively, 
this variant may signal LOH in this region, which is a known cause of PA (Thakker 2014). LOH 
in this locus affects MEN1 and AIP (Georgitsi et al. 2008). 
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Another interesting discovery was the association between two variants (rs7131056 and 
rs4938025) in the DRD2 gene and the extrasellar growth of neoplasms in hormone-secreting 
PAs. Extrasellar growth is usually observed in macroadenomas and tumors that have faster 
expansion rates and more severe clinical symptoms (as classified under the Hardy PA 
classification system as grade III or IV). Extrasellar growth is the primary reason why the 
majority of NFPAs are discovered since the mass of the expanding tumor compresses the 
optical nerve, internal carotid arteries or other surrounding tissue. This may result in visual 
field or color vision disturbances, or more unspecific symptoms such as vertigo, nausea and 
headaches (Powell 2003). In our study, 77% of our NFPA samples consisted of tumors with 
extrasellar growth. In functional PAs, such as prolactinomas and somatotropinomas, the 
primary cause of pathology is the overproduction of hormones while the tumor itself is a 
rarer cause of complications. Regardless, 46% of functional PAs were placed in the 
extrasellar growth category. This could be due to a number of reasons. It could be because, 
by the time the patient undergoes pituitary imaging, there has been such an increase in the 
adenoma cell proliferation rate that the tumor has already attained the size used in the 
classification system. It could also be that a particular PA secretes lower amounts of 
hormones and therefore causes milder symptoms, subsequently delaying the diagnosis. 
Similarly, it could be that a cell in NFPA gives rise to a new secretory lineage and that 
symptoms of hormonal imbalance thus only start when the tumor is already large. Lastly, it 
is also possible that some of the patients delay seeking medical help after the onset of early 
symptoms. DRD2 rs7131056, according to one report, was associated with social phobia 
(Sipila et al. 2010) giving some credence to the hypothesis of delayed visits to healthcare 
professionals. Other internal cellular mechanisms could also be involved. One example of 
this is when DRD2 physically forms heterodimers with SSTRs (Rocheville et al. 2000). As in 
most cases, the mechanism by which an intronic variant affects disease phenotype remains 
unclear (Cooper 2010). Seven variants of DRD2 protein have been found in humans and 
three more transcripts are made, two of them with retained intron where rs7131056 is 
located (Yates et al. 2016) providing range of possible mechanisms of action for the variant. 
Direct comparison of both PA studies must be performed carefully due to the different 
scopes of the studies. The initial study was focused on identifying potential drivers of 
somatotropinoma in a subgroup of a well-characterized patient group. Various biochemical 
analyses and patient history details were available in this study. The second study in which 
seven candidate genes in three types of pituitary adenomas was the focus, common variants 
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predisposing patients to PA and its three predominant subtypes was searched for. A limited 
amount of additional phenotypic data was collected due to incomplete patient records. This 
design was taken in order to obtain larger sample sizes since this would increase the power 
of the study in detecting more modest associations, and increase the chances of capturing 
PA subgroups with a common driver or variant/mutation. 
In the second study, the SSTR5 rs34037914 variant remained statistically significant in the 
expanded study group (P=0,003 before correcting for multiple testing). Compared to the OR 
of 3.38 from the initial study (CI 0.95=1.78-6.42), the OR remained similar at 2.63 in the 
second study (CI 0.95=1.36-5.38). The association of rs34037914 with PA was not statistically 
significant after correcting for the 62 independent tests that were made during the study. 
However, the decrease in rs34037914 minor allele frequency in the expanded 
somatotropinoma patient group confirmed that this variant contributes towards clinically 
more severe acromegaly with a pronounced phenotype and more complications during the 
course of therapy. These patients were therefore recognized earlier and thus more likely to 
be included in the initial discovery study. 
There were two more variants associated with the presence of acromegaly in the initial 
study. In the second study the rs642249 probe design was not working in the Illumina 
GoldenGate multiplex assay and no data was acquired. The SSTR5 rs169068 variant was not 
statistically significant in the second study, thus providing further evidence that its 
association in the initial study was due to high LD with the two lead SNPs. 
The initial somatotropinoma study raised awareness of PA and increased efforts were 
applied to contact endocrinologists outside of the Riga. This led to increased diagnosis rates 
of clinically milder forms of acromegaly and PA in general. This was probably also 
strengthened due to the relative depletion of obvious PA cases in the population as the 
study sample size increased. 
4.4 Research strategies of molecular basis in multifactorial diseases 
Understanding the molecular basis of multifactorial diseases and their complications will 
without a doubt lead to improved medical care. This may come in the form of novel drugs 
targeting newly discovered molecular pathways, an increase in treatments relating to gene 
expression, and possibly even gene editing therapies. In cases where the molecular basis of 
the disease is known, the main benefit for the patient would be precision medicine tailored 
to prevent the onset of the disease in the patient. Under such a model, the best available 
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therapy could be selected in order to manage disease prognosis and the likelihood of 
disease-associated complications.  
The initial excitement about the use of genetic information to estimate the risk of 
developing multifactorial diseases receded after the first set of negative results. However, 
the most recent research showed that, if applied correctly together with conventional 
knowledge, the use of a patient’s genetic information is possible and potentially beneficial. 
Together with the falling cost of genetic analysis it is also becoming a cost effective 
diagnostic option. The main advantage of genetic information is its relative stability and 
minimal changes throughout a person’s lifetime, unlike blood biomarkers. It can also be used 
to assess multiple multifactorial diseases, drug responses and disease phenotypes thus 
increasing the cost-to-benefit ratio. Once new discoveries are made and verified, their 
information can be added to the known genetic data of a person without the need for the 
individual to visit a medical facility for check-ups or additional laboratory testing. Although it 
has been suggested that the strength of genotype–phenotype associations is modified by 
age (Genin et al. 2011), genetic markers are likely to be predictive throughout an individual’s 
lifetime. This allows risk prediction to be performed much earlier in life, thus facilitating 
earlier primary prevention strategies in high-risk individuals. 
Current research strategies investigating the molecular basis of multifactorial diseases 
consist of multiple complementary tiers. Traditionally, GWAS with large case and control 
groups are used to identify possible disease-associated markers. In order to validate findings, 
a second GWAS is preferably performed and, in an ideal scenario, it is performed in a 
different population thereby facilitating the reduction in the number of variants of interest. 
This is typically followed by a period where smaller studies from all over the world target 
candidate genes and try to replicate the association in separate populations. Compared to 
initial discovery studies, candidate gene studies usually use more phenotypic information to 
understand the finer details of the association in the samples. Candidate gene studies are 
interesting since significant precision medicine aspects can emerge. This is because authors 
frame the aims of the studies differently and stratify the samples using phenotypic 
combinations in order to uncover finer details about the associations. It is important to 
obtain sufficient statistical power in these follow-up studies in order to obtain conclusive 
results and preferably report on the negative associations too. Then, of course, there are 
functional studies that investigate mechanisms by which molecular variation is translated 
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into different processes within cells, organs and the whole organism, as well as how they 
interact with and respond to an environment. 
Nowadays with the rapid advancement of DNA sequencing and editing technologies, the 
search for the molecular basis of multifactorial diseases has gained next level of momentum 
and the precision medicine is gaining an ever increasing importance in the modern 
biomedicine. 
 
  
101 
 
5. Conclusions 
1. Minor allele of the adenosine A3 receptor polymorphism rs35511654 is protective against 
CAD in Latvian population under additive and dominant models. 
2. Minor alleles of rs1130534 and rs1049346 in GLO1 are associated with decreased Glo1 
activity in Latvian population. 
3. Minor allele of rs2736654 in GLO1 is modulating observable GLO1 activity. 
4. There is no association between type 1 or type 2 diabetes and their respective 
complications and the three GLO1 polymorphisms that were studied in Latvian population. 
5. SSTR5 polymorphisms rs34037914 and rs642249 are associated with the presence of 
acromegaly in Latvian population. 
6. MEN1 polymorphism rs2959656 is associated with the presence of clinically significant 
pituitary adenoma in Latvian population. 
7. DRD2 polymorphisms rs7131056 and rs4938025 are associated with the extrasellar 
growth of hormones secreting pituitary adenomas. 
8. Germline polymorphisms of SSTR2, AIP, GNAS and PRAKR1A do not contribute to the 
development of PA in a significant proportion of patients in Latvian population. 
 
  
102 
 
6. Thesis for defense 
1. Polymorphisms in the adenosine A3 receptor are minor contributors and modulators of 
disease and disease outcome, and are involved in the pathophysiology of CAD. 
2. GLO1 genetic variants are strong determinants of glyoxalase activity, but are not 
associated with diabetes complications in Latvian population.  
3. SSTR5 polymorphism rs34037914 determines the severity of GH-secreting adenoma cases 
diagnosed with acromegaly. 
4. The MEN1 polymorphism rs2959656 is a strong predictor of the clinically significant 
presence of pituitary adenoma in Latvian population. 
5. Distinguishing between multifactorial disease sub-phenotypes improves the capacity to 
uncover new genetic factors.  
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Supplementary  
 Supplementary 1.1. Linkage disequilibrium plot of AIP and +/- 70 kb region. 
 Supplementary 1.2. Linkage disequilibrium plot of DRD2 and +20kb/- 70 kb region. 
 Supplementary 1.3. Linkage disequilibrium plot of GNAS and +/- 20 kb region. 
 
 Supplementary 1.4. Linkage disequilibrium plot of MEN1 and +/- 20 kb region. 
 
 
 
 
 
 
 
 
 
 Supplementary 1.5. Linkage disequilibrium plot of PRKAR1A and +/- 20 kb region. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Supplementary 1.6. Linkage disequilibrium plot of SSTR2 (above) and SSTR5 (below) and+/- 20 kb 
region. 
  
 Supplementary 2. Tag-SNPs used in pituitary adenoma study of 2016. 
 
CHR SNP Gene Gene context 
11 rs1620333 AIP 1 intron 
11 rs11214606 DRD2 1 intron 
11 rs12805897 DRD2 1 intron 
11 rs17529477 DRD2 1 intron 
11 rs2471857 DRD2 1 intron 
11 rs4936270 DRD2 1 intron 
11 rs4938019 DRD2 1 intron 
11 rs4938021 DRD2 1 intron 
11 rs7125415 DRD2 1 intron 
11 rs7131056 DRD2 1 intron 
11 rs2002453 DRD2 2 intron 
11 rs17847841 AIP 3' intergenic 
11 rs687376 AIP 3' intergenic 
11 rs10891549 DRD2 3' intergenic 
11 rs12422191 DRD2 3' intergenic 
11 rs2242592 DRD2 3' intergenic 
11 rs2734848 DRD2 3' intergenic 
11 rs2734849 DRD2 3' intergenic 
11 rs7944809 DRD2 3' intergenic 
11 rs11604662 AIP 3' nearby gene 
11 rs2276020 AIP syn D-D 
11 rs2734838 DRD2 3 intron 
11 rs624975 MEN1 3 intron 
11 rs2440390 DRD2 4 intron 
11 rs11603236 AIP 5' intergenic 
11 rs1638558 AIP 5' intergenic 
11 rs7114510 AIP 5' intergenic 
11 rs7936800 AIP 5' intergenic 
11 rs7948158 AIP 5' intergenic 
11 rs10736466 DRD2 5' intergenic 
11 rs10891564 DRD2 5' intergenic 
11 rs12292637 DRD2 5' intergenic 
11 rs17602285 DRD2 5' intergenic 
11 rs4245154 DRD2 5' intergenic 
11 rs4938025 DRD2 5' intergenic 
11 rs4938026 DRD2 5' intergenic 
11 rs6589382 DRD2 5' intergenic 
11 rs11601245 AIP 5' nearby gene 
11 rs1124492 DRD2 7 intron 
11 rs504195 MEN1 7 intron 
11 rs2959656 MEN1 missense A-T 
11 rs61741147 AIP missense A-V 
11 rs1800497 DRD2 missense E-K 
 CHR SNP Gene Gene context 
11 rs607969 MEN1 missense R-Q 
11 rs1801028 DRD2 missense S-C 
11 rs6274 DRD2 3' UTR variant 
11 rs2071313 MEN1 synonymous  D-D 
11 rs4986918 DRD2 synonymous L-L 
16 rs550713 SSTR5 1 intron 
16 rs197056 SSTR5 3' intergenic 
16 rs2076421 SSTR5 3'mRNS 
16 rs3751830 SSTR5 5' non coding transcript SSTR5  
16 rs4988484 SSTR5 missense A-V 
16 rs169068 SSTR5 missense P-L 
16 rs4988487 SSTR5 missense P-S 
16 rs34803442 SSTR5 missense V-M 
16 rs34037914 SSTR5 synonymous F-F 
16 rs642249 SSTR5 synonymous P-P 
17 rs1466113 SSTR2 1 intron 
17 rs714925 SSTR2 1 intron 
17 rs2015212 PRKAR1A 3' intergenic 
17 rs9925 PRKAR1A 3' mRNS 
17 rs11077670 SSTR2 5' intergenic 
17 rs2236753 SSTR2 SSTR2 processed transcript 
17 rs61743817 SSTR2 missense S-F 
17 rs7220818 SSTR2 3' UTR variant 
20 rs6026557 GNAS 1 intron 
20 rs6026560 GNAS 1 intron 
20 rs6026561 GNAS 1 intron 
20 rs16982305 GNAS 2 intron 
20 rs17804083 GNAS 2 intron 
20 rs4810148 GNAS 2 intron 
20 rs6026563 GNAS 2 intron 
20 rs6026567 GNAS 2 intron 
20 rs6026574 GNAS 2 intron 
20 rs6070638 GNAS 2 intron 
20 rs6100260 GNAS 2 intron 
20 rs7271854 GNAS 2 intron 
20 rs8125112 GNAS 2 intron 
20 rs234627 GNAS 3' intergenic 
20 rs6123837 GNAS 3 intron 
20 rs9679845 GNAS 3 intron 
20 rs3730164 GNAS 4 intron 
20 rs4812037 GNAS 5' intergenic 
20 rs6064714 GNAS 5' intergenic 
20 rs965808 GNAS 5' intergenic 
20 rs2057291 GNAS 5 intron 
20 rs13831 GNAS 6 intron 
 CHR SNP Gene Gene context 
20 rs3730168 GNAS 8 intron 
20 rs3730170 GNAS 8 intron 
20 rs6100269 GNAS 8 intron 
20 rs919197 GNAS 8 intron 
20 rs919196 GNAS 9 intron 
20 rs11554273 GNAS missense R-G 
20 rs79709641 GNAS missense R-H 
20 rs7121 GNAS synonymous I-I 
  
 Supplementary 3. Primers of SSTR5 amplification (A) and sequencing (B) 
A. PCR 
Oligonucleotide ID Lenght (bp) Sequence 
IVK-03-Fw 22 GCATGTGCTGGTTCAGGGACTC 
IVK-03-Rs 21 TGTGGCAGACGGTTAGAGGGG 
STR5p1Fw 19 CCCTGCTCCAGTGAATCTT 
STR5p1Rs 22 CTGAAATCTGGTAGACAAGGAA 
STR5p2Fw 21 GGGGATGTTGATTTCTAGGTT 
STR5p2Rs 20 GGAGGCTGAGTCAGGAGGAT 
STR5p3Fw 20 GGCTGGCGTGCAGTGGTGTA 
STR5p4Fw 18 AAGCTCCGATGGGACTGG 
STR5p4Rs 18 CACCTGCGTCTCCCTGAA 
STR5p5Fw 18 GCCTCGGCTCCTTACCTG 
STR5p5Rs 19 CACCAGCGTCCTGTTGTCA 
   
B. Sequencing 
Oligonucleotide ID Lenght (bp) Sequence 
IVK-03-Seq1f 20 CACCCTGGCGTCCTCCCTTC 
IVK-03-Seq2f 22 ACGGCGTCAACCAGTTCACCAG 
IVK-03-Seq3r 23 TGAGCAGGTAGCACAGGCAGATG 
IVK-03-Seq4r 20 CACCGCAGTGCAACCTCCGC 
STR5p1SFw 18 GTGAATCTTTCAACCCTC 
STR5p1SRs 20 GTAGACAAGGAAAGGAGAGC 
STR5p2SFw 18 ATTTCTAGGTTTGTTGAGC 
STR5p2SRs 19 TCAGGAGGATCATTTGAGC 
STR5p3SFw 18 CAGTGGTGTAATCACAGC 
STR5p3SRs 18 AGAGGCATAGCGTATGGG 
STR5p4SFw 18 GGGACTGGGCAGTGTCAG 
STR5p4SRs 19 TCCCTGAAGCCCCTCAGAG 
STR5p5SFw 18 CTTACCTGGTAGACGAGG 
STR5p5SRs 19 CTGTTGTCACCGCCTCCAG 
  
 Supplementary 4. Mini-sequencing primers 
Oligonucleotide ID Lenght (bp) Sekvence 
JAK-28-MS 18 GGCCLTGCTGGGCTTCTT [C/T] 
JAK-29.1-MS 19 CCGGATCLTGTCTGGACGC [A/G] 
JAK-29.2-MS 19 AGCLGCAGGAGGCCACGCC [A/G] 
 
  
 Supplementary 5. Results of main GWAS of CAD published until 2017. CHR – chromosome, POS – position, SNP – single nucleotide polymorphism, RA – risk allele, 
RAF – risk allele frequency, OR – odds ratio, CI – confidence interval, CAD – coronary artery disease, MI – myocardial infarction, NR – not reported, UTR – 
untranslated region, nc – non-coding. 
AUTHOR Year DISEASE REGION CHR_POS MAPPED_GENE SNP-RA CONTEXT RAF OR 95% CI 
Samani NJ 2007 CAD 6q25.1 150931849 MTHFD1L rs6922269-A intron 0,25 1,23 [1.15-1.33] 
Samani NJ 2007 CAD 2q36.3 226203364 LOC646736 rs2943634-C intergenic 0,65 1,21 [1.13-1.30] 
WTCCC 2007 CAD 9p21.3 22125504 CDKN2B rs1333049-C downstream_gene 0,47 1,47 [1.27-1.70] 
WTCCC 2007 CAD 1q43 240282296 FMN2 rs17672135-T intron 0,87 1,43 [1.23-1.64] 
WTCCC 2007 CAD 22q12.1 26293669 SEZ6L rs688034-T intron 0,31 1,11 [0.99-1.25] 
WTCCC 2007 CAD 16q23.3 83178793 CDH13 rs8055236-G intron 0,80 1,91 [1.33-2.74] 
Samani NJ 2007 CAD 1q41 222650187 MIA3 rs17465637-C intron 0,71 1,2 [1.12-1.30] 
Samani NJ 2007 CAD 9p21.3 22125504 CDKN2B rs1333049-C downstream_gene 0,47 1,36 [1.27-1.46] 
Samani NJ 2007 CAD 1p13.3 109279544 CELSR2 rs599839-A downstream_gene 0,77 1,29 [1.18-1.40] 
Samani NJ 2007 CAD 10q11.21 44258419 LINC00841 rs501120-T downstream_gene 0,87 1,33 [1.20-1.48] 
Samani NJ 2007 CAD 15q22.33 67166301 SMAD3 rs17228212-C intron 0,30 1,21 [1.13-1.30] 
Helgadottir 2007 MI 9p21.3 22124478 CDKN2B rs10757278-G downstream_gene 0,45 1,28 [1.22-1.35] 
Erdmann J 2009 CAD 3q22.3 138403280 MRAS rs9818870-T 3_prime_UTR 0,15 1,15 [1.11-1.19] 
Erdmann J 2009 CAD 12q24.31 120997784 HNF1A rs2259816-T synonymous 0,36 1,08 [1.05-1.11] 
Kathiresan S 2009 MI 9p21.3 22098575 CDKN2B rs4977574-G intron 0,56 1,29 [1.25-1.34] 
Kathiresan S 2009 MI 1p13.3 109275908 CELSR2 rs646776-T downstream_gene 0,81 1,19 [1.13-1.26] 
Kathiresan S 2009 MI 1q41 222650187 MIA3 rs17465637-C intron 0,72 1,14 [1.10-1.19] 
Kathiresan S 2009 MI 10q11.21 44280376 LINC00841 rs1746048-C downstream_gene 0,84 1,17 [1.11-1.24] 
Kathiresan S 2009 MI 21q22.11 34226827 LINC00310 rs9982601-T intron 0,13 1,2 [1.14-1.27] 
Kathiresan S 2009 MI 6p24.1 12927312 PHACTR1 rs12526453-C intron 0,65 1,12 [1.08-1.17] 
Kathiresan S 2009 MI 2q33.2 202881162 WDR12 rs6725887-C intron 0,14 1,17 [1.11-1.23] 
Kathiresan S 2009 MI 19p13.2 11052925 SMARCA4 rs1122608-G intron 0,75 1,15 [1.10-1.20] 
Kathiresan S 2009 MI 1p32.3 55030366 BSND rs11206510-T intergenic 0,81 1,15 [1.10-1.21] 
Tregouet D 2009 CAD 6q25.3 160541471 LPA rs7767084-T intron 0,16 1,2 [1.13-1.28] 
 AUTHOR Year DISEASE REGION CHR_POS MAPPED_GENE SNP-RA CONTEXT RAF OR 95% CI 
Tregouet 2009 CAD 6q25.3 160442500 SLC22A3 rs2048327-C intron 0,02 1,82 [1.57-2.12] 
Erdmann J 2010 CAD 10p11.23 30027143 KIAA1462 rs3739998-C missense 0,44 1,15 [1.11-1.20] 
Aoki A 2010 MI 5p15.33 4029676 LOC105374626 rs11748327-? downstream_gene NR 1,25 [1.18-1.33] 
Schunkert H 2011 CAD 1p32.3 55030366 BSND rs11206510-T intergenic 0,82 1,08 [1.05-1.11] 
Schunkert H 2011 CAD 10q11.21 44280376 LINC00841 rs1746048-C downstream_gene 0,87 1,09 [1.07-1.13] 
Schunkert H 2011 CAD 1p32.2 56497149 PPAP2B rs17114036-A intron 0,91 1,17 [1.13-1.22] 
Schunkert H 2011 CAD 6p21.31 35067023 ANKS1A rs17609940-G intron 0,75 1,07 [1.05-1.10] 
Schunkert H 2011 CAD 6q23.2 133893387 TCF21 rs12190287-C 3_prime_UTR 0,62 1,08 [1.06-1.10] 
Schunkert H 2011 CAD 7q32.2 130023656 ZC3HC1 rs11556924-C missense 0,62 1,09 [1.07-1.12] 
Schunkert H 2011 CAD 9q34.2 133278724 ABO rs579459-C upstream_gene 0,21 1,1 [1.07-1.13] 
Schunkert H 2011 CAD 10q24.32 102959339 CNNM2 rs12413409-G intron 0,89 1,12 [1.08-1.16] 
Schunkert H 2011 CAD 11q23.3 116778201 ZPR1 rs964184-G 3_prime_UTR 0,13 1,13 [1.10-1.16] 
Schunkert H 2011 CAD 13q34 110308365 COL4A2 rs4773144-G intron 0,44 1,07 [1.05-1.09] 
Schunkert H 2011 CAD 14q32.2 99667605 HHIPL1 rs2895811-C intron 0,43 1,07 [1.05-1.10] 
Schunkert H 2011 CAD 15q25.1 78796769 ADAMTS7 rs3825807-A missense 0,57 1,08 [1.06-1.10] 
Schunkert H 2011 CAD 17p13.3 2223210 SMG6 rs216172-C intron 0,37 1,07 [1.05-1.09] 
Schunkert H 2011 CAD 17p11.2 17640408 PEMT rs12936587-G intergenic 0,56 1,07 [1.05-1.09] 
Schunkert H 2011 CAD 17q21.32 48911235 UBE2Z rs46522-T nc_transcript_exon 0,53 1,06 [1.04-1.08] 
C4D 2011 CAD 9p21.3 22098575 CDKN2B rs4977574-G intron NR 1,2 [1.16-1.25] 
C4D 2011 CAD 1p13.3 109275908 CELSR2 rs646776-T downstream_gene NR 1,14 [1.09-1.19] 
C4D 2011 CAD 6p24.1 12888772 PHACTR1 rs1332844-T intron NR 1,11 [1.07-1.15] 
C4D 2011 CAD 10q23.31 89243170 LIPA rs1412444-T intron 0,42 1,09 [1.07-1.12] 
C4D 2011 CAD 11q22.3 103789839 LOC105369463 rs974819-T intron 0,32 1,07 [1.04-1.09] 
C4D 2011 CAD 15q25.1 78818751 ADAMTS7 rs4380028-C intron 0,65 1,07 [1.05-1.10] 
C4D 2011 CAD 7q22.3 107604100 BCAP29 rs10953541-C intron 0,80 1,08 [1.05-1.11] 
C4D 2011 CAD 10p11.23 30046193 KIAA1462 rs2505083-C intron 0,38 1,07 [1.04-1.09] 
C4D 2011 CAD 6p24.1 12903725 PHACTR1 rs9349379-? intron NR 
 C4D 2011 CAD Xq23 110695977 CHRDL1 rs5943057-? intron NR 
 
 AUTHOR Year DISEASE REGION CHR_POS MAPPED_GENE SNP-RA CONTEXT RAF OR 95% CI 
C4D 2011 CAD 4q31.22 147126398 LOC105377476 rs1395821-? intergenic NR 
 C4D 2011 CAD 15q24.1 74741059 CYP1A1 rs2472299-? intergenic NR 
 C4D 2011 CAD 2q32.1 187331742 LOC105373786 rs840616-? intron NR 
 C4D 2011 CAD 17q12 33960430 LOC107985038 rs11650066-? intron NR 
 C4D 2011 CAD 17q23.3 64330939 PECAM1 rs6504218-? intron NR 
 C4D 2011 CAD 2q32.1 187478770 LOC105373786 rs7586970-? missense NR 
 C4D 2011 CAD 1p32.2 56500678 PPAP2B rs17114046-? intron NR 
 C4D 2011 CAD 9q22.33 97977842 HEMGN rs4743150-? intergenic NR 
 Schunkert H 2011 CAD 1p13.3 109279544 CELSR2 rs599839-A downstream_gene 0,78 1,11 [1.08-1.15] 
Schunkert H 2011 CAD 1q41 222650187 MIA3 rs17465637-C intron 0,74 1,14 [1.09-1.20] 
Schunkert H 2011 CAD 2q33.2 202881162 WDR12 rs6725887-C intron 0,15 1,14 [1.09-1.19] 
Schunkert H 2011 CAD 3q22.3 138401110 MRAS rs2306374-C intron 0,18 1,12 [1.07-1.16] 
Schunkert H 2011 CAD 6p24.1 12927312 PHACTR1 rs12526453-C intron 0,67 1,1 [1.06-1.13] 
Schunkert H 2011 CAD 6q25.3 160540105 LPA rs3798220-C missense 0,02 1,51 [1.33-1.70] 
Schunkert H 2011 CAD 9p21.3 22098575 CDKN2B rs4977574-G intron 0,46 1,29 [1.23-1.36] 
Schunkert H 2011 CAD 12q24.12 111446804 SH2B3 rs3184504-T missense 0,44 1,07 [1.04-1.10] 
Schunkert H 2011 CAD 19p13.2 11052925 SMARCA4 rs1122608-G intron 0,77 1,14 [1.09-1.18] 
Schunkert H 2011 CAD 21q22.11 34226827 LINC00310 rs9982601-T intron 0,15 1,18 [1.12-1.24] 
Schunkert H 2011 CAD 2q37.1 233133771 INPP5D rs10933436-A intron 0,49 1,06 [1.04-1.09] 
Schunkert H 2011 CAD 3p25.1 15606497 BTD rs7651039-C nc_transcript_exon 0,54 1,06 [1.04-1.09] 
Schunkert H 2011 CAD 7q31.2 117427768 ASZ1 rs7808424-G intron 0,12 1,1 [1.06-1.14] 
Schunkert H 2011 CAD 11q24.2 126412002 ST3GAL4 rs4937126-G intron 0,69 1,06 [1.04-1.09] 
Schunkert H 2011 CAD 17p13.3 2222311 SMG6 rs1231206-A intron 0,37 1,07 [1.05-1.09] 
C4D 2011 CAD 10q24.32 102959339 CNNM2 rs12413409-? intron NR 
 Wild PS 2011 CAD 9p21.3 22125504 CDKN2B rs1333049-C downstream_gene 0,49 1,27 [1.23-1.31] 
Wild PS 2011 CAD 9p21.3 22031006 CDKN2B rs7865618-A intron 0,59 1,18 [1.14-1.21] 
Wild PS 2011 CAD 10q23.31 89243170 LIPA rs1412444-T intron 0,32 1,1 [1.07-1.14] 
Wild PS 2011 CAD 6q25.3 159225301 FNDC1 rs365302-C intron 0,24 1,11 [1.06-1.15] 
 AUTHOR Year DISEASE REGION CHR_POS MAPPED_GENE SNP-RA CONTEXT RAF OR 95% CI 
Wild PS 2011 CAD 6q14.1 81805598 LOC105377873 rs16893526-G intergenic 0,91 1,13 [1.07-1.21] 
Slavin TP 2011 CAD 1q21.1 146039391 TRH rs12091564-C upstream_gene NR 
 Slavin TP 2011 CAD 3q26.1 162443828 LOC107986049 rs11924705-C intergenic NR 
 Slavin TP 2011 CAD 4p16.2 5366258 STK32B rs7697839-G intron NR 
 Slavin TP 2011 CAD 9p21.3 22125504 CDKN2B rs1333049-G downstream_gene NR 
 Slavin TP 2011 CAD 12q23.3 103924394 GNN rs1165668-G intron NR 
 Slavin TP 2011 CAD 1q21.1 146018957 HFE2 rs10218795-C intron NR 
 Slavin TP 2011 CAD 3q26.1 162449608 LOC107986049 rs6789378-A intergenic NR 
 Slavin TP 2011 CAD 4p16.2 5366497 STK32B rs7673097-G intron NR 
 Slavin TP 2011 CAD 9p21.3 22125348 CDKN2B rs1333048-G downstream_gene NR 
 Slavin TP 2011 CAD 12q23.3 103924218 GNN rs1165668-G intron NR 
 Mehta NN 2011 CAD 6p24.1 12903725 PHACTR1 rs9349379-? intron NR 
 Mehta NN 2011 CAD 1p32.2 56500678 PPAP2B rs17114046-? intron NR 
 Takeuchi F 2011 CAD 6p21.32 32701596 HLA rs11752643-T downstream_gene 0,06 1,26 [1.15-1.38] 
Takeuchi F 2011 CAD 9p21.3 22115287 CDKN2B rs944797-C intron 0,46 1,25 [1.18-1.31] 
Takeuchi F 2011 CAD 12q24.12 111803962 ALDH2 rs671-A missense 0,23 1,43 [1.35-1.51] 
Davies RW 2012 CAD 6p21.33 31216419 HCG27 rs3869109-G regulatory_region NR 1,14 [NR] 
Davies RW 2012 CAD 1q21.3 154465420 IL6R rs2229238-? 3_prime_UTR NR 1,45 [NR] 
Davies RW 2012 CAD 6p21.1 43791136 VEGFA rs6905288-T downstream_gene NR 1,23 [NR] 
Davies RW 2012 CAD 6q16.1 96632322 FHL5 rs12200560-? intergenic NR 1,11 [NR] 
Davies RW 2012 CAD 2q35 215420652 FN1 rs17458018-? intron NR 1,22 [NR] 
Hager J 2012 CAD 6p24.1 12903725 PHACTR1 rs9349379-G intron 0,35 1338 [1.22-1.47] 
Hager J 2012 CAD 6p24.1 12903725 PHACTR1 rs9349379-G intron 0,35 1187 [1.22-1.44] 
Hager J 2012 CAD 6p24.1 12903725 PHACTR1 rs9349379-G intron 0,35 1,23 [1.14-1.33] 
Lu X 2012 CAD 2p24.1 19745816 LOC105373461 rs2123536-T intergenic 0,39 1,12 [1.08-1.16] 
Lu X 2012 CAD 4q32.1 155590307 LOC105377504 rs1842896-T intergenic 0,76 1,14 [1.10-1.19] 
Lu X 2012 CAD 6p21.32 32373576 LOC101929163 rs9268402-G upstream_gene 0,59 1,16 [1.12-1.20] 
Lu X 2012 CAD 12q21.33 89687411 ATP2B1 rs7136259-T intron 0,39 1,11 [1.08-1.15] 
 AUTHOR Year DISEASE REGION CHR_POS MAPPED_GENE SNP-RA CONTEXT RAF OR 95% CI 
Lu X 2012 CAD 9p21.3 22096056 CDKN2B rs10757274-G intron 0,46 1,37 [1.31-1.43] 
Lu X 2012 CAD 12q24.13 112379979 HECTD4 rs11066280-A intron 0,17 1,19 [1.13-1.25] 
Lu X 2012 CAD 6p24.1 12903725 PHACTR1 rs9349379-G intron 0,74 1,15 [1.10-1.21] 
Lu X 2012 CAD 6q23.2 133875536 TARID rs12524865-C intron 0,61 1,11 [1.06-1.16] 
Lee JY 2013 CAD 12q24.11 111241410 CUX2 rs886126-T intron 0,66 1,14 [1.08-1.20] 
Lee JY 2013 CAD 12q24.11 110912851 MYL2 rs3782889-C intron 0,21 1,26 [1.19-1.34] 
Lee JY 2013 CAD 13q12.3 28409926 FLT1 rs9508025-C intron 0,50 1,14 [1.08-1.20] 
Lee JY 2013 CAD 9p21.3 22103814 CDKN2B rs1333042-? intron NR 1,3 [1.19-1.41] 
Lee JY 2013 CAD 12q24.12 111730205 ACAD10 rs11066015-A intron NR 1,41 [1.27-1.56] 
Hirokawa M 2014 MI 3p24.3 17082892 PLCL2 rs4618210-G intron 0,44 1,1 [1.06-1.14] 
Hirokawa M 2014 MI 19p13.3 2160530 AP3D1 rs3803915-C intron 0,19 1,12 [1.09-1.16] 
Hirokawa M 2014 MI 9p21.3 22098575 CDKN2B rs4977574-C intron 0,46 1,22 [1.12-1.33] 
Hirokawa M 2014 MI 12q24.12 111672685 BRAP rs3782886-A synonymous 0,26 1,46 [1.33-1.60] 
Reilly MP 2011 CAD 15q25.1 78787892 ADAMTS7 rs1994016-C intron 0,60 1,19 [1.13-1.24] 
Reilly MP 2011 MI in CAD    rs514659-C  0,37 1,21 [1.13-1.29] 
Reilly MP 2011 CAD 1p13.3 109275908 CELSR2 rs646776-T downstream_gene 0,79 1,33 [1.22-1.44] 
Reilly MP 2011 CAD 9p21.3 22098575 CDKN2B rs4977574-G intron 0,53 1,3 [1.22-1.39] 
Lettre G 2011 CAD 5q31.3 142484039 LOC101926941 rs17577085-? intron 0,46 2,63 [1.72-3.85] 
Lettre G 2011 CAD 7q36.1 151423862 WDR86 rs13232179-A upstream_gene 0,11 1,67 [1.36-2.06] 
Lettre G 2011 CAD 13q31.1 84480131 LINC00333 rs9546711-A intergenic 0,42 1,66 [1.35-2.04] 
Nikpay M 2015 CAD 4q12 56972417 NOA1 rs17087335-T intron 0,21 1,06 [1.04-1.09] 
Nikpay M 2015 CAD 7q36.1 150993088 NOS3 rs3918226-T intron 0,06 1,14 [1.09-1.19] 
Nikpay M 2015 CAD 15q22.33 67163292 SMAD3 rs56062135-C intron 0,79 1,07 [1.05-1.10] 
Nikpay M 2015 CAD 15q26.1 89030987 LOC100129942 rs8042271-G intergenic 0,90 1,1 [1.06-1.14] 
Nikpay M 2015 CAD 17q23.2 60936127 BCAS3 rs7212798-C intron 0,15 1,08 [1.05-1.11] 
Nikpay M 2015 CAD 18q21.32 60171168 RNU4 rs663129-A intergenic 0,26 1,06 [1.04-1.08] 
Nikpay M 2015 CAD 22q11.23 24262890 BCRP1 rs180803-G intron 0,97 1,2 [1.13-1.27] 
 AUTHOR Year DISEASE REGION CHR_POS MAPPED_GENE SNP-RA CONTEXT RAF OR 95% CI 
Nikpay M 2015 CAD 19q13.11 32391114 LOC400684 rs12976411-A intron 0,09 1,49 [1.35-1.67] 
Nikpay M 2015 CAD 12q24.23 117827636 KSR2 rs11830157-G intron 0,36 1,12 [1.08-1.16] 
Nikpay M 2015 CAD 11p15.4 9729649 SWAP70 rs10840293-A intron 0,55 1,06 [1.04-1.08] 
Nikpay M 2015 CAD 9p21.3 22098620 CDKN2B rs2891168-G intron 0,49 1,21 [1.19- 1.24] 
Nikpay M 2015 CAD 6p24.1 12903725 PHACTR1 rs9349379-G intron 0,43 1,14 [1.12- 1.16] 
Nikpay M 2015 CAD 6q25.3 160584578 LPA rs55730499-T intron 0,06 1,37 [1.31- 1.44] 
Nikpay M 2015 CAD 6q26 160702419 PLG rs4252185-C intron 0,06 1,34 [1.28- 1.41] 
Nikpay M 2015 CAD 1p13.3 109274570 CELSR2 rs7528419-A 3_prime_UTR 0,79 1,12 [1.10- 1.15] 
Nikpay M 2015 CAD 15q25.1 78832133 LOC390614 rs4468572-C intron 0,59 1,08 [1.06- 1.10] 
Nikpay M 2015 CAD 21q22.11 34221526 LINC00310 rs28451064-A intron 0,12 1,14 [1.10- 1.17] 
Nikpay M 2015 CAD 19p13.2 11077571 SMARCA4 rs56289821-G intergenic 0,90 1,14 [1.11- 1.18] 
Nikpay M 2015 CAD 10q11.21 43985363 LINC00841 rs1870634-G intergenic 0,64 1,08 [1.06- 1.10] 
Nikpay M 2015 CAD 1p32.2 56499992 PPAP2B rs9970807-C intron 0,92 1,13 [1.10- 1.17] 
Nikpay M 2015 CAD 1q41 222650401 MIA3 rs67180937-G intron 0,66 1,08 [1.06- 1.11] 
Nikpay M 2015 CAD 10q23.31 89243170 LIPA rs1412444-T intron 0,37 1,07 [1.05- 1.09] 
Nikpay M 2015 CAD 
 
rs2519093-T 
 
0,19 1,08 [1.06- 1.11] 
Nikpay M 2015 CAD 6q23.2 133852013 LINC01312 rs12202017-A intron 0,70 1,07 [1.05- 1.09] 
Nikpay M 2015 CAD 10p11.23 30034963 KIAA1462 rs2487928-A intron 0,42 1,06 [1.04- 1.08] 
Nikpay M 2015 CAD 7q32.2 130023656 ZC3HC1 rs11556924-C missense 0,69 1,08 [1.05- 1.10] 
Nikpay M 2015 CAD 12q21.33 89615182 ATP2B1 rs2681472-G intron 0,20 1,08 [1.05- 1.10] 
Nikpay M 2015 CAD 11q22.3 103802549 LOC105369463 rs2128739-A intron 0,32 1,07 [1.05- 1.09] 
Nikpay M 2015 CAD 19q13.32 44919689 APOC1 rs4420638-G downstream_gene 0,17 1,1 [1.07- 1.13] 
Nikpay M 2015 CAD 7p21.1 19009765 HDAC9 rs2107595-A regulatory_region 0,20 1,08 [1.05- 1.10] 
Nikpay M 2015 CAD 13q34 110388334 COL4A2 rs11838776-A intron 0,26 1,07 [1.05- 1.09] 
Nikpay M 2015 CAD 2p11.2 85561052 GGCX rs7568458-A intron 0,45 1,06 [1.04- 1.08] 
Nikpay M 2015 CAD 4q31.22 147359849 MIR548G rs4593108-C intergenic 0,80 1,07 [1.05- 1.10] 
Nikpay M 2015 CAD 12q24.12 111446804 SH2B3 rs3184504-T missense 0,42 1,07 [1.04- 1.09] 
Nikpay M 2015 CAD 1q21.3 154423470 IL6R rs6689306-A intron 0,45 1,06 [1.04- 1.08] 
 AUTHOR Year DISEASE REGION CHR_POS MAPPED_GENE SNP-RA CONTEXT RAF OR 95% CI 
Nikpay M 2015 CAD 2q22.3 144528992 LINC01412 rs17678683-G upstream_gene 0,09 1,1 [1.07- 1.14] 
Nikpay M 2015 CAD 10q24.32 102845159 PFN1P11 rs11191416-T intron 0,87 1,08 [1.05- 1.11] 
Nikpay M 2015 CAD 4q32.1 155718736 GUCY1A3 rs72689147-G intron 0,82 1,07 [1.05- 1.10] 
Nikpay M 2015 CAD 14q32.2 99679373 HHIPL1 rs10139550-G 3_prime_UTR 0,42 1,06 [1.04- 1.08] 
Nikpay M 2015 CAD 2p24.1 19742712 LOC105373461 rs16986953-A intergenic 0,10 1,09 [1.06- 1.12] 
Nikpay M 2015 CAD 6p21.2 39166323 SAYSD1 rs56336142-T regulatory_region 0,81 1,07 [1.04- 1.09] 
Nikpay M 2015 CAD 1p32.3 55030366 BSND rs11206510-T intergenic 0,85 1,08 [1.05- 1.11] 
Nikpay M 2015 CAD 15q26.1 90873320 FURIN rs17514846-A intron 0,44 1,05 [1.03- 1.07] 
Nikpay M 2015 CAD 17p13.3 2223210 SMG6 rs216172-C intron 0,35 1,05 [1.03- 1.07] 
Nikpay M 2015 CAD 8q24.13 125478730 TRIB1 rs2954029-A intron 0,55 1,04 [1.03- 1.06] 
Nikpay M 2015 MI 10q24.32 102834750 CYP17A1 rs1004467-A nc_transcript_exon 0,87 1,08 [1.05-1.11] 
Nikpay M 2015 MI 14q32.2 99679373 HHIPL1 rs10139550-G 3_prime_UTR 0,41 1,05 [1.03-1.07] 
Nikpay M 2015 MI 2p11.2 85534925 RPSAP22 rs10176176-T upstream_gene 0,47 1,07 [1.05-1.09] 
Nikpay M 2015 MI 6q25.3 160589086 LPA rs10455872-G intron 0,05 1,33 [1.27-1.4] 
Nikpay M 2015 MI 1p32.3 55030366 BSND rs11206510-T intergenic 0,85 1,08 [1.05-1.11] 
Nikpay M 2015 MI 7q32.2 130023656 ZC3HC1 rs11556924-C missense 0,70 1,07 [1.05-1.1] 
Nikpay M 2015 MI 13q34 110165755 COL4A1 rs11617955-T intron 0,90 1,09 [1.05-1.12] 
Nikpay M 2015 MI 1q21.3 154424940 IL6R rs12118721-T intron 0,48 1,06 [1.04-1.08] 
Nikpay M 2015 MI 10q23.31 89243662 LIPA rs1332329-C intron 0,36 1,08 [1.06-1.1] 
Nikpay M 2015 MI 6p21.2 39156672 SAYSD1 rs1544935-T intergenic 0,81 1,08 [1.05-1.10] 
Nikpay M 2015 MI 2p24.1 19742712 LOC105373461 rs16986953-A intergenic 0,09 1,08 [1.05-1.12] 
Nikpay M 2015 MI 2q22.3 144528992 LINC01412 rs17678683-G upstream_gene 0,09 1,08 [1.05-1.11] 
Nikpay M 2015 MI 22q11.23 24262890 BCRP1 rs180803-G intron 0,97 1,21 [1.14-1.28] 
Nikpay M 2015 MI 10q11.21 43985363 LINC00841 rs1870634-G intergenic 0,62 1,07 [1.05-1.09] 
Nikpay M 2015 MI 8q24.13 125466208 TRIB1 rs2001846-T upstream_gene 0,49 1,05 [1.03-1.07] 
Nikpay M 2015 MI 11q22.3 103798234 LOC105369463 rs2019090-A intron 0,36 1,07 [1.05-1.09] 
Nikpay M 2015 MI 6q26 160687112 LPA rs2315065-A intergenic 0,06 1,3 [1.24-1.36] 
Nikpay M 2015 MI 10p11.23 30046193 KIAA1462 rs2505083-C intron 0,39 1,06 [1.04-1.08] 
 AUTHOR Year DISEASE REGION CHR_POS MAPPED_GENE SNP-RA CONTEXT RAF OR 95% CI 
Nikpay M 2015 MI 15q26.1 90894158 FES rs2521501-T intron 0,29 1,07 [1.04-1.09] 
Nikpay M 2015 MI 12q21.33 89615182 ATP2B1 rs2681472-G intron 0,19 1,08 [1.05-1.1] 
Nikpay M 2015 MI 21q22.11 34221526 LINC00310  rs28451064-A intron 0,12 1,13 [1.09-1.17] 
Nikpay M 2015 MI 9p21.3 22098620 CDKN2B rs2891168-G intron 0,48 1,21 [1.19-1.23] 
Nikpay M 2015 MI 1q41 222638065 MIA3 rs35700460-G intron 0,65 1,09 [1.06-1.11] 
Nikpay M 2015 MI 17q21.32 48982960 GIP rs35895680-C intergenic 0,72 1,06 [1.03-1.08] 
Nikpay M 2015 MI 4q31.22 147359849 MIR548G rs4593108-C intergenic 0,80 1,07 [1.04-1.09] 
Nikpay M 2015 MI 
 
rs532436-A 
 
0,19 1,12 [1.09-1.14] 
Nikpay M 2015 MI 19p13.2 11077477 SMARCA4 rs55791371-A intergenic 0,90 1,11 [1.07-1.15] 
Nikpay M 2015 MI 13q34 110390962 COL4A2 rs55940034-G intron 0,27 1,07 [1.04-1.09] 
Nikpay M 2015 MI 19q13.32 44919589 APOC1 rs56131196-A downstream_gene 0,16 1,09 [1.06-1.12] 
Nikpay M 2015 MI 12q24.12 111569952 ATXN2 rs653178-C intron 0,44 1,08 [1.06-1.1] 
Nikpay M 2015 MI 15q25.1 78830996 ADAMTS7  rs7165042-C intron 0,56 1,06 [1.04-1.09] 
Nikpay M 2015 MI 17q23.2 60936127 BCAS3 rs7212798-C intron 0,15 1,07 [1.04-1.1] 
Nikpay M 2015 MI 4q32.1 155718736 GUCY1A3 rs72689147-G intron 0,82 1,08 [1.05-1.1] 
Nikpay M 2015 MI 15q22.33 67149412 SMAD3 rs72743461-C intron 0,80 1,07 [1.05-1.1] 
Nikpay M 2015 MI 1p13.3 109274570 CELSR2 rs7528419-A 3_prime_UTR 0,80 1,11 [1.08-1.13] 
Nikpay M 2015 MI 6p24.1 12903725 PHACTR1 rs9349379-G intron 0,41 1,14 [1.12-1.16] 
Nikpay M 2015 MI 17p13.3 2229956 SMG6 rs9914266-C intron 0,35 1,05 [1.03-1.07] 
Nikpay M 2015 MI 1p32.2 56499992 PPAP2B rs9970807-C intron 0,92 1,12 [1.08-1.16] 
Dehghan A 2016 CAD 13q31.3 91102945 LINC00380 rs16945184-C intergenic NR 1,20 [1.11-1.3] 
Dehghan A 2016 CAD 6p21.2 40414972 LRFN2 rs2916260-T intron NR 1,15 [1.09 - 1.22] 
Dehghan A 2016 MI 6q26 163609768 QKI rs6941513-G intergenic NR 1,2 [1.13-1.28] 
Dehghan A 2016 MI 4q35.1 182703491 TENM3 rs7692395-G intron NR 1,45 [1.27-1.69] 
Dehghan A 2016 MI 7p21.2 14815437 DGKB rs4721377-T intron NR 1,26 [1.14-1.38] 
Dehghan A 2016 MI 16q24.1 86651813 FOXL1 rs4843416-G intron NR 1,43 [1.22-1.67] 
Wakil SM 2016 CAD 2q33.1 198223806 PLCL1 rs7421388-G intron 0,79 1,30 [NR] 
Wakil SM 2016 CAD 3q25.31 156287165 KCNAB1 rs13082914-T intron 0,22 1,21 [NR] 
 AUTHOR Year DISEASE REGION CHR_POS MAPPED_GENE SNP-RA CONTEXT RAF OR 95% CI 
Wakil SM 2016 CAD 4q31.23 150108918 DCLK2 rs9985766-G intron 0,16 1,35 [NR] 
Wakil SM 2016 CAD 5q11.2 52889863 ITGA1 rs16880442-G nc_transcript_exon 0,93 1,39 [NR] 
Wakil SM 2016 CAD 6q25.3 156266980 LOC101928923 rs17775862-T intergenic 0,06 1,55 [NR] 
Wakil SM 2016 CAD 8q21.11 72230147 LOC392232 rs12541758-T nc_transcript_exon 0,40 1,25 [NR] 
Wakil SM 2016 CAD 9p21.3 22088095 CDKN2B rs10738607-G intron 0,64 1,28 [NR] 
Wakil SM 2016 CAD 9q31.3 111690726 C9orf84 rs10981012-A intron 0,13 1,34 [NR] 
Wakil SM 2016 CAD 10q11.21 44280862 LINC00841 rs1746049-C downstream_gene 0,72 1,25 [NR] 
Wakil SM 2016 MI 3q25.1 149875124 RNF13 rs41411047-A intron 0,09 1,51 [NR] 
Wakil SM 2016 MI 4q31.23 150108918 DCLK2 rs9985766-G intron 0,16 1,23 [NR] 
Wakil SM 2016 MI 5p13.3 32073460 PDZD2 rs32793-G intron 0,28 1,25 [NR] 
Wakil SM 2016 MI 5q11.2 52889863 ITGA1 rs16880442-G nc_transcript_exon 0,93 1,41 [NR] 
Wakil SM 2016 MI 8q12.3 63191534 YTHDF3 rs4739066-A intron 0,86 1,37 [NR] 
Wakil SM 2016 MI 8q21.11 72230147 LOC392232 rs12541758-T nc_transcript_exon 0,40 1,16 [NR] 
Wakil SM 2016 MI 9p21.3 22088095 CDKN2B-AS1 rs10738607-G intron 0,63 1,27 [NR] 
Wakil SM 2016 MI 17q25.3 80133738 GAA rs7211079-A downstream_gene 0,77 1,30 [NR] 
Wakil SM 2016 MI 21q22.11 34226827 LINC00310 rs9982601-T intron 0,16 1,38 [NR] 
 
